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Normal motor signaling in the basal ganglia requires regulating which movements to 
suppress and which to enact. In Parkinson's disease, loss of dopamine levels due to loss of 
dopaminergic neurons results in unbalanced basal ganglia output and loss of motor control. 
Motor sequences are thought to be triggered by cortical inputs as these glutamatergic inputs 
provide the main excitatory drive to the striatal output neurons. Dopamine is a crucial modulator 
of corticostriatal activity and loss of its normal function plays an important role in the 
pathophysiology of Parkinson's disease. We hypothesize that the functional reorganization of the 
cortical inputs to the striatum following long-term dopamine depletion as well as the response to 
dopamine replacement therapies has important functional implications in the pathogenesis and 
treatment of Parkinson's disease motor symptoms. 
To address this hypothesis, we adapted an optical technique using lipophilic dye, FM 1-
43, to characterize the activities of the two major classes of corticostriatal projection neurons - 
the ipsilateral and contralateral cortical projections – and compared the influence of dopamine 
D2 receptors on these inputs. We found that both cortical projections shared similar patterns of 
terminal release and were both inhibited by D2 receptor activation. A D2 receptor-mediated 
inhibition specifically targeted the least active (slow-releasing) corticostriatal inputs with low 
	  	  
probability of release. This “filtering" effect by D2 receptors confirmed a role for dopamine in 
modulating excitatory cortical inputs that could be crucial to selection of proper motor functions. 
To study the loss of motor control during conditions of chronic dopamine depletion, we 
employed a classic Parkinson's disease rodent model in which dopamine is depleted from one 
hemisphere using the neurotoxin, 6-hydroxydopamine. Behavior tests confirmed lateralized 
motor response due to loss of function in the forelimb contralateral to the side of lesion. The 
effect of chronic dopamine depletion on corticostriatal synaptic activity was assessed by 
comparing the activity between the dopamine-intact and dopamine-lesioned hemispheres. We 
proposed that in the dopamine-intact hemisphere, D2 receptor activation exerted selective 
inhibitory influence or "filtering" on corticostriatal signaling through two mechanisms: 
presynaptic D2 receptors directly inhibiting glutamate release and postsynaptic D2 receptor-
mediated retrograde endocannabinoid inhibition activating presynaptic CB1 receptors. However, 
in the dopamine-lesioned hemisphere, there was a supersensitive inhibition by D2 receptor 
activation and the "filtering" effect was lost: the "filtering" was partially restored by concurrently 
activating D2 receptors and inhibiting CB1 receptors. 
We then tested whether this endocannabinoid-mediated restoration of D2 receptor 
"filtering" in corticostriatal inputs had an effect on motor function in vivo. We examined changes 
in motor function and corticostriatal activity in 6-OHDA lesioned mice following DA 
replacement therapy with L-DOPA in combination with modulators of endocannabinoid 
transmission. We found that treatment with L-DOPA alone or with L-DOPA + URB597 (an 
inhibitor of endocannabinoid breakdown) reduced contralateral akinesia and in fact led to a 
contralateral limb use preference. Following L-DOPA treatment, corticostriatal presynaptic 
activity was depressed in the lesioned striata and D2 receptor-mediated inhibition was occluded. 
	  	  
Treatment of L-DOPA with the CB1 receptor antagonist, AM251, completely normalized motor 
function. This treatment regime also completely normalized basal corticostriatal activity on the 
lesioned hemisphere, and the D2 receptor "filtering" effect was restored. 
Our findings confirm that dopamine modulates excitatory corticostriatal activity 
presynaptically via D2 receptor activation, a portion of which is due to cannabinoid effects. 
Furthermore, a correlation between dopamine-induced loss of motor function and loss of 
corticostriatal "filtering" by D2 receptors was demonstrated by the fact that dopamine 
replacement treatment that restores behavior also preserves this "filtering" mechanism in 
corticostriatal inputs. These findings suggest that dopaminergic "filtering" of particular 
corticostriatal synaptic activity contributes to motor commands. 
	  i	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 Parkinson’s disease (PD) is the second most common neurodegenerative disorder, 
affecting 1% of the general population at age 65, and increasing in prevalence with age (de Lau 
and Breteler 2006). PD is primarily a sporadic disorder with unknown etiology; however, a small 
fraction of clinical cases (~10%) can be linked to known genetic mutations (Singleton, Farrer et 
al. 2013). In both sporadic and genetic PD, the disorder is characterized by an inability to 
translate motor commands into coordinated movement resulting in resting tremor or shaking, 
bradykinesia (slowed movement), akinesia (loss of voluntary movement), rigidity or stiffness of 
the limbs due to resistance to movement, and postural instability due to impaired balance. The 
pathological hallmarks of PD are the loss of dopaminergic neurons in the substantia nigra pars 
compacta (SNc) and the subsequent loss of dopaminergic innervations to the striatum, and the 
presence of ubiquitinated alpha-synuclein inclusions known as Lewy bodies and Lewy neurites. 
The loss of SNc neurons occurs progressively throughout the course of the disease, but clinical 
onset of motor symptoms appear when ~30% of SNc dopamine (DA) neurons are lost (Burke 
and O'Malley 2013). 
Since PD was first characterized by James Parkinson in 1817, effective treatments to 
delay the progress of PD have not been developed, but clinical treatments can temporarily 





dopaminergic replacement therapy using the precursor for DA, L-3,4-dihydroxyphenlalanine 
(levodopa, or L-DOPA). Administration of L-DOPA increases the DA concentrations in the brain 
and improves motor dysfunctions in PD patients during early stages of the disease. Clinically, 
within minutes of the first dose of L-DOPA, there is a substantial improvement of motor 
disability (Nutt, Woodward et al. 1992, Nutt and Holford 1996). However, chronic L-DOPA 
treatment is associated with an increased risk of motor complications, such as dyskinesias 
(involuntary motor fluctuations) (Schrag, Ben-Shlomo et al. 1998). Approximately 30% of PD 
patients experience dyskinesias after 4-6 years of L-DOPA treatment and close to 90% of 
patients suffer from this complication after 9 years (Ahlskog and Muenter 2001). Additionally, 
as the disease progresses, the effectiveness of L-DOPA subsides, leading to periods of “wearing 
off” of the therapeutic benefit in which the beneficial effects of medication diminish during or 
toward the end of a dose (Lang and Lozano 1998, Lang and Lozano 1998, Obeso, Olanow et al. 
2000). The lack of effective long-term treatments for PD might be addressed by gaining a better 
understanding of the mechanisms responsible.  
 
6-OHDA Rodent Model of Parkinson's Disease 
 To study the synaptic changes induced by chronic DA depletion and assess the 
effectiveness of therapeutics to normalize these changes, we will utilize a rodent model of PD. 
Toxin-induced animal models mimic the PD-associated neurodegeneration of dopaminergic 
neurons in the SNc. One such model, the 6-hydroxydopamine (6-OHDA)-lesioned rodent, 
provides a well-characterized and reproducible means to kill DA neurons. In this model, 





blood-brain barrier and must be stereotaxically injected directly into the brain to selectively 
disrupt or destroy catecholaminergic systems (Ungerstedt 1968, Blum, Torch et al. 2001). When 
injected into the striatum, 6-OHDA produces a protracted retrograde degeneration of 
dopaminergic neurons in the SNc over the span of several weeks (Przedborski, Levivier et al. 
1995, Simola, Morelli et al. 2007). Upon entering the neuron via the DA transporter (DAT), 6-
OHDA exerts an oxidative stress response generating toxicity that leads to dopaminergic cell 
death. Unilateral injection of 6-OHDA provides a within-subject comparison of striatal synaptic 
changes in the DA-intact and DA-lesioned hemispheres. Importantly for our research, the 
functional difference between the intact and lesioned hemispheres gives rise to lateralized 
behavioral responses that are quantifiable. Using the unilateral 6-OHDA mouse model, it will be 
possible to explore the interaction between DA and corticostriatal terminals in the striatum and 
specifically address how this interaction influences motor command signaling.   
 
Basal Ganglia 
Motor symptoms associated with PD are linked to the loss of SNc DA neurons, which 
disrupts the basal ganglia (BG) circuit resulting in debilitating disruption of coordinated motor 
function. The BG is an interconnected group of subcortical structures involved in coordinating 
information from sensorimotor, motivational, and cognitive brain areas to control behaviors such 
as movement and reward learning. The BG is comprised of the striatum, the external and internal 
segments of the globus pallidus (GPe and GPi), the subthalamic nucleus (STN), and the 
substantia nigra (SN) (Figure 1.1). Input signals to the BG from the cortex and thalamus 





the BG output nuclei via the direct and indirect pathways (Gerfen 1992). The direct pathway is a 
monosynaptic pathway to the GPi and the substantia nigra pars reticulata (SNr) (Figure 1.1; 
blue). The indirect pathway is a polysynaptic pathway to the GPi/SNr via the GPe and the STN 
(Figure 1.1; red). The GPi/SNr neurons project to several thalamic nuclei which then complete 
the circuit by innervating prefrontal, premotor, and motor cortical areas.  
Another major projection to the striatum is the midbrain DA neurons from the SNc and 
ventral tegmental area (VTA). Direct and indirect striatal pathway signals can be altered by DA 
input which facilitates transmission along the direct pathway and inhibits transmission along the 
indirect pathway (Gerfen, Engber et al. 1990). In terms of motor function, increased locomotion 
is attributed to activation of direct pathway MSNs, whereas decreased locomotion is attributed to 
activation of indirect pathway MSNs. Together, dopaminergic and excitatory corticostriatal 
inputs modulate the direct pathway to initiate specific movements while concurrently activating 
the indirect pathway to suppress competing motor networks (Figure 1.1).  
Motor disorders associated with basal ganglia dysfunction, such as PD, have been 
attributed to the disruption of equilibrium between direct and indirect striatal pathways (Albin, 
Young et al. 1989). Chronic DA depletion results in an imbalance of striatal output pathways - 
the direct pathway is made less active by diminishing MSN discharge activity and 
responsiveness to cortical input whereas output along the indirect pathway is increased, resulting 
in an overall inhibition of movement (Mallet, Ballion et al. 2006). As the main excitatory drive 
onto striatal neurons, glutamatergic input from the cortex plays a pivotal role in PD symptoms. 








Figure 1.1. Functional organization of the basal ganglia. (A) Simplified BG circuitry model 
representing direct pathway (blue) and indirect pathway (red). Excitatory glutamatergic inputs 
(grey), dopaminergic inputs (black) and inhibitory GABAergic inputs (white) (Fisone, 
Hakansson et al. 2007). (B) Schematic of the direct pathway via D1-R MSNs (blue) and indirect 
pathway via D2-R MSNs (red). Normal motor signaling requires excitatory cortical inputs and 
dopaminergic input from the SNc to activate the direct and indirect pathways to initiate specific 
movements and suppress competing motor networks, respectively (Gerfen, Engber et al. 1990). 
 
The Striatum 
The striatum is the major input region of the basal ganglia and is composed primarily of 
MSNs which represent 90-95% of all cells in this structure (Kemp and Powell 1971). MSNs 
utilize γ-aminobutyric acid (GABA) as a neurotransmitter (Bolam, Hanley et al. 2000). The 





expression of neuropeptides and neurotransmitter receptors in each cell type. Direct pathway 
MSNs express substance P and dynorphin and express DA D1 receptors, whereas indirect 
pathway MSNs express enkephalin and DA D2 receptors (Gerfen, Engber et al. 1990, Lei, Jiao et 
al. 2004). MSNs receive glutamatergic inputs from the cortex and thalamus that terminate 
predominantly on spines (Kemp and Powell 1971) and dopaminergic inputs from the midbrain 
that synapse on MSN dendrites and spine necks (Cowan and Wilson 1994, Smith, Bennett et al. 
1994). 
 In addition to MSNs, there are four types of aspiny interneurons - (1) tonically active 
giant aspiny cholinergic neurons (TANs) and three types of GABAergic interneurons: (2) fast 
spiking interneurons that express parvalbumin, (3) low-threshold spiking interneurons that 
express somatostatin-, neuropeptide Y-, and nitric oxide synthase, and (4) those that express 
calretinin (Cowan, Wilson et al. 1990, Wilson, Chang et al. 1990, Bennett and Bolam 1993). 
Receiving inputs from cortical and thalamic projections, striatal interneurons can also modulate 
striatal output by modulating MSNs and other interneurons (Tepper, Koos et al. 2004). 
 
Divisions of the striatum 
 Three major divisions of the striatum can be made based on differences in efferent and 
afferent connections, physiology, and contributions to BG-mediated behavior: dorsal versus 






Dorsal and Ventral Striatum 
 The striatum is anatomically and functionally distinct and can be defined by differences 
in afferent connections (Joel and Weiner 1994, Yin and Knowlton 2006). Within the dorsal 
striatum, the dorsolateral region receives somatotopically organized sensorimotor information 
from the cortex and the dorsomedial region receives inputs from association cortices (Kunzle 
1975, Kitai, Kocsis et al. 1976, Donoghue and Herkenham 1986) (Figure 1.2 D and D). DAergic 
innervation to the dorsal striatum is primarily from the SNc. The ventral striatum (or nucleus 
accumbens) receives limbic afferents from the amygdala and hippocampus. DAergic innervation 
to the ventral striatum is primarily from the VTA (Voorn, Vanderschuren et al. 2004). 
Distinctions between the dorsal and ventral striatum can also be made in terms of function and 
relative contribution to behavioral processes. The dorsal striatum has been associated with 
procedural habits, whereas the ventral striatum is involved in motivation and reward learning and 
is the primary site of action for drugs of abuse (Joel and Weiner 2000). 
 
Patch and Matrix Compartments 
  The patch and matrix compartments can be differentiated on the basis of the afferent and 
efferent projections (Gerfen 1992). The matrix compartments (~80-90% of striatal volume) 
receive afferents from the cortex and thalamus and send efferents to the GP and SNr (Donoghue 
and Herkenham 1986, Gerfen 1992). The striatal matrix is also associated with sensorimotor 
information and can be distinguished from the patch compartments by the presence of calbindin 





volume) receive afferents from limbic and frontal cortical regions and send efferents to the SNc 
which can modulate dopaminergic input into the striatum (Gerfen 1985, Graybiel 1990). 
 
Indirect and Direct Projection Pathways  
 As described above, the two major efferent neurons of the striatum are characterized as 
direct striatonigral and indirect striatopallidal MSNs. These anatomically defined cell 
populations have distinct physiological and signaling properties and can be modulated 
independently to result in different behavioral outcomes. Under normal conditions, these output 
pathways work synergistically to produce coordinated effects on motor behavior. When signaling 
is imbalanced, such as occurs in PD, there are distinct disruptions which occur in each pathway 
that ultimately result in loss of motor control (Albin, Young et al. 1989, Gerfen, Engber et al. 
1990, Gerfen 2000). 
 
Striatal Neurotransmitter Systems 
Glutamate 
 Glutamatergic input from the cortex and thalamus provides the primary excitatory drive 
to striatal MSNs which is essential to motor signaling. Glutamate acts on AMPA and NMDA 
ionotropic receptors expressed on striatal cells which control the influx of sodium (Na2+) and 
calcium (Ca2+) into these neurons. AMPA and NMDA receptors are involved in mediating 





depression (LTD). LTP and LTD are important forms of synaptic plasticity expressed at 
corticostriatal synapses and may underlie striatal functions such as motor and reward learning 
(Calabresi, Picconi et al. 2007). Disruptions in normal LTP and LTD are seen in response to drug 
abuse and during dyskinesias resulting from abnormal responses to chronic L-DOPA DA 
replacement therapy in PD (Picconi, Paille et al. 2008).  
 In addition to ionotropic glutamatergic transmission, glutamate also acts on metabotropic 
glutamate receptors (mGluRs) expressed in the striatum. The mGluRs can be differentiated into 
two groups: mGluR1 receptors that are expressed postsynaptically on MSNs and interneurons of 
the striatum as well as presynaptically on DAergic neurons of the SNc where they can modulate 
DA release to the striatum (Zhang and Sulzer 2003); and mGluR2 receptors that are expressed 
presynaptically on corticostriatal nerve terminals and can negatively regulate glutamate release 
onto striatal cells (Lovinger and McCool 1995).  
 
Dopamine  
DA plays a fundamental role in basal ganglia function and motor signaling (Nicola, 
Surmeier et al. 2000). The striatum is densely innervated by DAergic fibers originating in the 
SNc (dorsal striatum) and VTA (ventral striatum). The DA neuron axonal projections are highly 
dense with a single axon ~467,000 µm average length (Matsuda, Furuta et al. 2009) and DAergic 
boutons represent ~10% of all striatal synapses (Groves, Linder et al. 1994).  
 DA receptors (DA-Rs) are seven transmembrane domain metabotropic receptors that are 





classes based on structural, pharmacological, and signaling properties: D1-like receptors (D1-Rs) 
include the D1 and D5 subtypes and D2-like receptors (D2-Rs) include D2, D3, and D4 
subtypes. D1 and D2 receptors differ functionally in the intracellular signaling pathways they 
modulate with signaling cascades that often mediate opposite effects (Fisone, Hakansson et al. 
2007). D1-Rs couple to Golf proteins which activate adenylyl cyclase (AC) and increase the 
production of cyclic adenosine monophosphate (cAMP) to activate protein kinase A (PKA) 
(Stoof and Kebabian 1981). In contrast, D2-Rs couple to Gi proteins that inhibit AC, resulting in 
decreasing cAMP and PKA activity (Stoof and Kebabian 1981). PKA regulates the function of 
cellular substrates such as voltage-gated K+, Na+, Ca2+ channels, ionotropic glutamate, and 
GABA receptors and transcription factors. DA-Rs can also signal independently of cAMP/PKA 
to modulate intracellular Ca2+ levels and regulate ligand- and voltage-gated ion channels via the 
phopholipase C (PLC)/protein phosphatase-2b cascade. 
DA-Rs are present in every cell type in the striatum. D1 and D2 receptors are localized 
presynaptically in nerve terminals and axonal varicosities, as well as postsynaptically in dendritic 
shafts and spines (Hersch, Ciliax et al. 1995). In the dorsal striatum, D1-Rs may be exclusively 
localized on striatonigral MSNs (Hersch, Ciliax et al. 1995, Dumartin, Doudnikoff et al. 2007). 
In contrast, D2-Rs are localized on pre- and postsynaptic elements in the dorsal striatum. 
Electron microscopy studies identified D2 label on some presynaptic terminals of DA afferents 
(Sesack, Aoki et al. 1994), glutamatergic cortical and thalamic afferents (Hersch, Ciliax et al. 
1995, Wang and Pickel 2002), as well as on postsynaptic elements (striatopallidal MSNs) 







The endocannabinoid (eCB) system can act as a modulator of DAergic neurotransmission 
in the basal ganglia (Pertwee and Wickens 1991, Cadogan, Alexander et al. 1997, Glass and 
Felder 1997, Giuffrida, Parsons et al. 1999, Beltramo, de Fonseca et al. 2000, Gerdeman and 
Lovinger 2001, Gubellini, Picconi et al. 2002). The effect on DA signaling is indirect because 
DA neurons do not express cannabinoid receptors (Julian, Martin et al. 2003) and cannabinoid 
ligands are without effect on electrically evoked DA release (Szabo, Muller et al. 1999). In the 
striatum, eCBs provide an important modulatory mechanism in the ﬁne-tuning of ongoing 
activity and generation of locomotor activity. The most abundant eCBs are anadamide (AEA or 
archidonyl-ethanolamide) and 2-arachidonoylglycerol (2-AG). These eCBs can function as 
retrograde messengers that regulate a variety of brain functions through stimulation of 
cannabinoid receptor 1 (CB1-R), a receptor highly enriched in the basal ganglia (Herkenham, 
Lynn et al. 1991, Tsou, Brown et al. 1998, Marsicano and Lutz 1999).  
CB1-Rs are expressed virtually throughout the CNS from the cortex to spinal cord 
regions, specifically in brain areas that contribute to movement (Figure 1.2). In the striatum, 
CB1-Rs co-localize with DA D1 and D2 receptors in striatal neurons (Herkenham, Lynn et al. 
1990, Herkenham, Lynn et al. 1991, Marsicano and Lutz 1999, Hermann, Marsicano et al. 2002, 
Van Waes, Beverley et al. 2012). CB1-Rs are primarily expressed in the motor and sensorimotor 
sectors of the striatum, with comparatively minimal expression in associative and limbic striatal 
regions (Van Waes, Beverley et al. 2012) (Figure 1.2). Within the striatum, they are 
predominantly localized on presynaptic terminals, but postsynaptic localization on dendrites and 





1999, Hohmann and Herkenham 2000, Matyas, Yanovsky et al. 2006). Presynaptic localization 
of CB1-Rs has also been reported specifically in glutamatergic terminals of corticostriatal 
projecting neurons (Uchigashima, Narushima et al. 2007). 
 
 
Figure 1.2. Topographical map of CB1-Rs and corticostriatal sensorimotor inputs. (A) 
Autoradiography of sagittal section of rodent brain (Herkenham, Lynn et al. 1990) shows 
abundance of CB1-R in region associated with the basal ganglia (B) Autoradiography of coronal 
section of rodent brain (Van Waes, Beverley et al. 2012) shows regional distribution of CB1-R 
expression in the dorsolateral striatum. (C) Schematic of mapping corticostriatal inputs shows 
predominantly motor (M1 and M2) and sensorimotor (SS) cortical projections to the dorsolateral 
striatum (Van Waes, Beverley et al. 2012). (D) Schematic of corticostriatal projection show that 
inputs controlling forelimb motor function (green) are projected to the dorsolateral striatum 






Synaptic depression mediated by eCBs involves retrograde signaling in which a 
postsynaptic stimulus is followed by a presynaptic CB1-mediated synaptic depression (Wilson 
and Nicoll 2001, Kano, Ohno-Shosaku et al. 2009).  Synthesized from membrane-derived lipid 
precursors, eCBs are released from postsynaptic MSNs (Calabresi, Picconi et al. 2007) when 
triggered by activation of postsynaptic D2-Rs and metabotropic glutamate receptors (mGluR-1) 
in combination with activation of L-type voltage-gated Ca2+ channels and postsynaptic 
depolarization (Choi and Lovinger 1997, Giuffrida, Parsons et al. 1999, Gubellini, Picconi et al. 
2002). Evidence suggests that eCBs released from MSNs are primarily AEA, not 2-AG 
(Fernandez-Espejo, Caraballo et al. 2005, Gonzalez, Scorticati et al. 2006). AEA acts indirectly 
as a retrograde messenger by binding to CB1-Rs located in corticostriatal inputs and has been 
found to suppress glutamate release, induce LTD in corticostriatal synapses, and inhibit 
dopaminergic function in the striatum (Yin, Davis et al. 2006, Kreitzer and Malenka 2007, 
Wang, Dever et al. 2012). 
 
Adenosine  
Adenosine is another important modulatory neurotransmitter in the striatum. Synthesis of 
adenosine occurs during the breakdown of intracellular ATP, which is transported to the 
extracellular space via transporter molecules. Adenosine functions through two types of G-
protein coupled metabotropic receptors, A1 and A2A, that are both highly expressed in the brain 





A1-Rs are expressed in both types of striatal projection neurons and on presynaptic 
dopaminergic nerve terminals (Ferre, Fredholm et al. 1997) and exert their influence by coupling 
to G proteins to inhibit cAMP and PKA signaling. These receptors have been shown to modulate 
DA signaling in direct and indirect pathway MSNs via presynaptic DA modulation as well as 
through second messenger signaling (Yabuuchi, Kuroiwa et al. 2006).  
A2A-Rs are highly expressed in the striatum where they are selectively localized to 
indirect pathway MSNs and function by coupling to Golf proteins to stimulate cAMP and PKA 
(Kull, Svenningsson et al. 2000). These receptors form heteromeric complexes with D2-Rs in 
striatopallidal neurons to inhibit D2-R signaling (Ferre, Fredholm et al. 1997, Yabuuchi, 
Kuroiwa et al. 2006, Shen, Coelho et al. 2008, Lerner and Kreitzer 2012). Other findings have 
suggested co-expression of D2- and A2A-Rs on TANs (Brown, James et al. 1990, Tozzi, de Iure 
et al. 2011). Additionally, recent evidence demonstrates the presence of A2A-Rs on 
glutamatergic corticostriatal terminals contacting direct pathway MSN dendritic spines (Quiroz, 
Lujan et al. 2009). A2A-Rs were reported to modulate excitation of glutamatergic transmission 
directly and also in combination with CB1-Rs (Quiroz, Lujan et al. 2009, Martire, Tebano et al. 
2011).  
 
Striatal Microcircuit  
 Taken together, the BG integrates inputs from multiple brain regions and 
neurotransmitters allowing for selective processing of motor and cognitive functions. DA 





pivotal to proper execution of motor commands. Electron microscopy studies indicate that the 
typical arrangement of dopaminergic and corticostriatal terminals is a three-element circuit 




Figure 1.3. Striatal Microcircuit. (A) Electron microscopy image of a DAT-labeled axon 
terminal (T) in contact with a dendritic spine (Sp), a small unlabeled dendrite (UD), and an 
asymmetric synapse from an unlabeled terminal (UT). Asymmetric terminals are frequently 
characterized as glutamatergic terminals (Nirenberg, Vaughan et al. 1996). (B) Schematic of the 
striatal microcircuit. The glutamatergic (GLU) projection from the cortex makes asymmetric 
synaptic contact with dendritic spines of a striatal projection neuron (MSN). MSNs in the 







 Each MSN receives input from a wide range of cortical cells; one estimate suggests that 
projections from over 5,000 cortical cells may converge upon a single MSN (Kincaid, Zheng et 
al. 1998). The cerebral cortex sends axonal projections to the striatum where they synapse on 
MSNs through: 1) ipsilateral collaterals of corticospinal neurons (PT-type corticostriatal 
neurons) and, 2) cortical fibers that project bilaterally that do not project to the spinal cord (IT-
type corticostriatal neurons) (Wilson 1987, Flaherty and Graybiel 1991, Cowan and Wilson 
1994). The functional differences between these two types of corticostriatal inputs will be 
explored in Aim 1 of this thesis. 
 In electron microscopy studies, glutamatergic terminals generally display an asymmetric 
synaptic density with docked vesicles close to the spine head, whereas DA terminals are usually 
associated with the spine neck and shaft and display a relatively small symmetric synaptic 
density (Totterdell, Bolam et al. 1984). Glutamate and DA inputs often appear to touch, although 
they do not form axo-axonal synapses (Nirenberg, Vaughan et al. 1996) (Figure 1.3 A). 
 Proper motor execution requires the DA and glutamate systems of the striatal 
microcircuit to coordinate in the activation of striatal synapses while inhibiting others (Gerfen 
1992, Lei, Jiao et al. 2004). However, in the DA-depleted state, DA modulation of MSNs and 
corticostriatal inputs is altered. Chronic DA depletion inhibits the discharge activity and 
responsiveness of corticostriatal inputs to direct pathway neurons and enhances those of indirect 
pathway neurons (Mallet, Ballion et al. 2006). Also, following DA depletion, glutamatergic 
synapses and spines from D2-R striatopallidal neurons are lost whereas no change in spine 





of DA depletion on the activity of corticostriatal inputs in the striatum is the primary focus of 
this thesis. 
 
D2-Rs and Corticostriatal Inputs 
 Many studies have confirmed that modulations in DA signaling can depress 
corticostriatal release probability via D2-Rs. In assays of glutamate release from striatal (Hsu, 
Huang et al. 1995) synaptosomes, D2 agonist, quinpirole, inhibited glutamate release (Maura, 
Giardi et al. 1988). Also, using microdialysis, D2 agonists were shown to depress glutamate 
release in the striatum (Yamamoto and Davy 1992). When superfused DA is applied to a striatal 
slice, the resulting inhibition of MSN excitation driven by stimulation of the cortex is blocked by 
D2-R antagonist, sulpiride (Hsu, Huang et al. 1995), indicating that D2-R activation inhibits the 
corticostriatal synapse. D2-R actions on corticostriatal terminals were also confirmed by 
comparing WT and D2 knockout animals depleted of DA using 6-OHDA in which the decrease 
in the probability of corticostriatal transmission was D2-R-dependent (Cepeda, Hurst et al. 
2001). Studies of direct measurements of corticostriatal activity performed by Nigel Bamford in 
collaboration with our lab also determined that DA acting through D2-Rs elicits a heterosynaptic 
decrease of presynaptic release probability of glutamate from corticostriatal afferents onto MSNs 
in the dorsal and ventral striatum (Bamford, Robinson et al. 2004, Bamford, Zhang et al. 2004, 
Bamford, Zhang et al. 2008).  
 These results suggest that DA exerts an inhibitory role on corticostriatal activity via D2-





D2-Rs or by the involvement of postsynaptic D2-Rs and retrograde activation of CB1-Rs.  
Evidence supporting a role of presynaptic D2-Rs includes studies of synaptosomes, isolated 
synaptic terminals, from rodent dorsal striatum in which D2-Rs located on the presynaptic 
corticostriatal terminals were found to modulate the release of glutamate (Maura, Giardi et al. 
1988) and electron microscopy studies that estimate D2-Rs expressed in ~30% of glutamatergic 
synapses (Wang and Pickel 2002, Dumartin, Doudnikoff et al. 2007). By in situ hybridization, 
D2 mRNA was restricted to corticocortical and corticostriatal layer 5 pyramidal neurons 
(Gaspar, Bloch et al. 1995). In acute brain slices, the presynaptic modulatory effect of DA can be 
measured by analysis of tetrodotoxin-resistant miniature excitatory or inhibitory postsynaptic 
currents (mEPSCs or mIPSCs), paired pulse ratios or evoked excitatory or inhibitory 
postsynaptic currents (EPSCs or IPSCs). Using this method, it has been reported that D2-R 
agonists have small effects on mEPSCs (Nicola and Malenka 1998) and their effects can be 
prevented by postsynaptic Ca2+ manipulation and pharmacological and genetic blockade of 
mGluRs and endocannabinoid receptors (Yin, Davis et al. 2006, Tozzi, de Iure et al. 2011, 
Wang, Dever et al. 2012). These findings support the premise of a DA and glutamate interaction 
in which postsynaptic D2-Rs decrease presynaptic drive from corticostriatal inputs through the 
synthesis of eCB retrograde messengers acting on presynaptic CB1-Rs. This observation is also 
supported by functional imaging studies of corticoaccumbal (glutamatergic projections from the 
prefrontal cortex to the nucleus accumbens) activity, which demonstrated that D2-R inhibition of 
cortical inputs can be blocked by antagonists of mGluR-1 (Wang, Dever et al. 2012). Together, 
these studies assign the inhibitory influence of D2-Rs on DA modulation of postsynaptic release 





controversy of D2-R inhibition via presynaptic or postsynaptic mechanism will be studied in 










The overall goal of this thesis is to investigate how dopamine modulates corticostriatal inputs 
during motor command signaling. Using a unilateral 6-OHDA mouse model of PD, the 
overarching hypothesis of this body of work is: 
 
Cortical inputs to the striatum have important functional implications in the pathogenesis of 
Parkinson's disease motor symptoms following long-term dopamine depletion as well as the 
response to dopamine replacement therapies. Modulation of excitatory corticostriatal input 
activity by dopamine significantly contributes to motor command signaling that underlies proper 
motor function.  
 
 






Ipsilateral and Contralateral Corticostriatal Inputs 
 
In this chapter, we characterize corticostriatal projections by modifying previous FM 1-43 
methodology to examine contralateral corticostriatal inputs. 
 
Introduction 
 The striatum is the major point of entry into the basal ganglia for information originating 
from the cortex and regulates motor control, cognition, habit learning, and addiction. The 
majority (~ 85%) of total synapses in the striatum are formed by cortical axonal projections to 
the striatum where they form asymmetrical synapses on medium spiny neurons (MSNs), the 
striatal output neurons (Kemp and Powell 1971). These asymmetrical synapses are characteristic 
of excitatory glutamatergic terminals. Two distinct types of cortical pyramidal neurons project to 
the striatum (Wilson 1987, Flaherty and Graybiel 1991, Reiner, Jiao et al. 2003, Parent and 
Parent 2006, Sohur, Padmanabhan et al. 2012) that originate from distinct cortical layers and 
follow a different trajectory into the striatum (Figure 2.1). The intratelencephalic (IT) type 
cortical neurons project bilaterally to ipsilateral and contralateral striatum (Wilson 1987). The 
other major class of corticostriatal neurons, the pyramidal tract (PT) type neurons, send an 
ipsilateral striatal collateral of the main axon through the pyramidal tract on its way to the brain 
stem and spinal cord (Landry, Wilson et al. 1984, Reiner, Jiao et al. 2003). Striatal collaterals of 
PT neurons make sparse en passant arborizations in the striatum while providing a major 





more extensive arborization pattern in dense clusters within the striatum (Cowan and Wilson 
1994, Reiner, Jiao et al. 2003, Parent and Parent 2006).  
 Both IT and PT terminals were seen to make asymmetric synaptic contacts with dendritic 
spines of direct and indirect pathway MSNs, responsible for promoting and suppressing motor 
movements, respectively. Some studies have reported distinct targets of the two corticostriatal 
types:  PT-type terminals preferentially contact D2 spines (21.3% contact D1 spines versus 
50.5% contact D2 spines), whereas IT-type terminals preferentially contact D1 spines (12.6% 
contact D2 spines versus 50.9% contact D1 spines) (Lei et al, 2004). Other studies determined IT 
synapses contact similar numbers of striatonigral and striatopallidal dendrites (Hersch, Ciliax et 
al. 1995, Ballion, Mallet et al. 2008). It may be that IT neurons provide the main excitatory input 
to both populations of striatal projection neurons as the PT input was found to be much weaker 







Fig 2.1 Schematic of the distinct connectivity of IT-type and PT-type corticostriatal neurons. (A) 
Targets of corticostriatal ipsilateral PT-type inputs (blue; CStrPNp) and bilateral IT-type inputs 
(red; CStrPNi) are differentiated from cortico-cortico callosal inputs (green; CPN) (Sohur, 
Padmanabhan et al. 2012). (B) From axon tracing studies, it has been shown that IT and PT 
neurons have distinct patterns of innervations in the striatum. PT neurons make small 
arborizations in the striatum and provide a major projection directly to motor neurons in the 
spinal cord and brainstem. (C) IT neurons have a more extensive arborization pattern within the 
striatum only (Cowan and Wilson 1994). 
 
Cortical IT neurons contain axons that bifurcate at the corpus callosum to facilitate 





cortico-cortical and corticostriatal connections (Cowan and Wilson 1994, Garcez, Henrique et al. 
2007). Contralateral IT neurons can project to both striata (~15%), while some IT neurons are 
devoid of commisural projections, and a small subset (~8%) targets both striata as well as the 
contralateral cortex (Jones and Wise 1977, Donoghue and Herkenham 1986, Wilson 1987, 
Parent and Parent 2006, Sohur, Padmanabhan et al. 2012). The target of IT neuron projections 
appears to be region-specific: motor cortex, but not somatosensory cortex, projects heavily 
contralaterally. These studies indicate clear topographical differences between IT and PT 
neurons and also suggest that since not all IT neurons contain both ipsilateral and contralateral 
projections, there may be functional differences within IT neurons themselves. Among multiple 
species—human, rat, monkey, and mice—the contralateral IT input is the only fiber tract devoted 
solely to integration of information from the two cortical hemispheres via the corpus callosum. 
 Divergence of IT and PT neurons by morphology and anatomical connectivity indicates 
potential functional differences between cortical inputs. The functional characteristics of IT and 
PT cortical inputs are addressed in the following aim: 
 
Aim 1: Are contralateral corticostriatal inputs (IT-type neurons) functionally discrete from 









Brain Slice Preparation 
 In order to study the contralateral corticostriatal inputs and their modulation by DA in a 
brain slice preparation, intact fibers need to be preserved. On the basis of the synaptic 
connectivity determined by previous axon tracing studies and retrograde labeling studies (Wilson 
1987, Cowan and Wilson 1994, Lei, Jiao et al. 2004), a 350 µm coronal slice preparation 
sectioned at a 30 degree angle was used to preserve a maximal number of ipsilateral and 
contralateral axonal projections to the striatum (Figure 2.2 A). To maintain angle consistency 
between experiments, an agar block with a 30 degree angle on its surface was placed under the 
brain during brain slice preparation at the vibratome.  
 All animals used for slice preparation were 2 to 4 month old male C57BL/6 mice 
obtained from Jackson Laboratory. All animal protocols were approved by the Institutional 
Animal Care and Use Committee of Columbia University. For striatal slice preparation, mice 
were decapitated and angled coronal slices were cut on a vibratome and allowed to recover for 1 
h before use at room temperature in oxygenated [95% O2, 5% CO2 (vol/vol)] ACSF	  containing 
the following (in mM): 125 NaCl, 2.5 KCl, 26 NaHCO3, 0.3 KH0PO4, 2.4 CaCl2, 1.3 MgSO4, 0.8 







Figure 2.2. Methodology for FM1-43 Experiments. (A) Schematic of 30 degree coronal slice 
(bottom) used to preserve maximum number of ipsilateral (black) and contralateral (red) 
projections (top) (Wilson 1987). (B) Schematic of placement of stimulation in of cortical inputs 
in layer V and imaging region of cortical terminals in dorsolateral striatum. (C) Representative 
time course of destaining in contralateral dorsal striatum during 10 Hz stimulation. Arrows 
indicated distinct terminals that have been loaded and unloaded with FM1-43. Stimulation begins 
at t = 0 sec. 
 
FM 1-43 Loading and Destaining 
When neuronal terminals are electrically stimulated, the endocytic styryl dye FM 1-43 
(N-[3(triethylammonio)propyl]-4-(4-dibutylaminostyryl) pyridinium dibromide) can label 
synaptic vesicles (Betz, Mao et al. 1992). FM dyes differ from other fluorescent tracers in that 
they are “amphiphilic” and, due to the hydrophobic tail and hydrophilic head, partition into 






Figure 2.3. FM 1-43 Protocol. (A) Chemical structure of FM 1-43 allows for the dye to brightly 
label extracellular membranes. (B) and (C) Protocol for: FM 1-43 dye penetration into 
membranes (1), stimulation-induced endocytosis of FM 1-43 (2), and subsequent release of dye 
using stimulation-induced exocytosis (3) in the presence of ADVASEP-7 (Betz, Mao et al. 1992, 
Bamford, Zhang et al. 2004). 
 
FM 1-43 was loaded into and released from corticostriatal terminals by electrical 
stimulation of the motor cortex in layer V, providing a simultaneous measurement of the activity 
of multiple synaptic terminals (Figure 2.2 B). The optimal location for the placement of 
stimulating electrodes was in the deep layers of the cortex, which allowed for a more selective 
stimulation of cortical afferents without inducing DA release from DA terminals within the 
striatum (Bamford, Zhang et al. 2004, Yin, Davis et al. 2006).  FM 1-43 (8 µM) was loaded into 
corticostriatal terminals by stimulating the cortex at 10 Hz for 10 min with 350 µA, 200 µs 





changes in release of FM 1-43 were not due to inadequate FM 1-43 loading of the recycling 
synaptic vesicle pool (Bamford, Robinson et al. 2004, Joshi, Wu et al. 2009). A stimulus 
frequency of 10 Hz was used in all experiments, as this frequency is consistent with 
physiological corticostriatal neuron firing rate (Stern, Kincaid et al. 1997), and is sensitive for 
detecting responses to pharmacological and physiological manipulations (Bamford, Robinson et 
al. 2004). Following terminal loading, slices were superfused in ADVASEP-7 (AD-7) for 20 min 
to remove adventitious staining. For stimulation-dependent destaining, pulse trains were again 
delivered to the cortex. Following exocytosis of recycling dye-loaded vesicles, FM 1-43 was 
released into the extracellular medium or was dispersed in the surrounding membrane; the 
decline in the fluorescence intensity of the terminal can be measured as it is desorbed from the 
membrane (Figure 2.2C and 2.3B). During unloading, ACSF is supplemented with AD-7 to 
prevent recurrent endocytosis of dye into synaptic terminals. Electrical stimulation was provided 
by a Grass Stimulator (West Warwick, RI) through a stimulation isolator (AMPI, Jerusalem, 
Israel) and monitored by a Tektronix TDS 3014B digital oscilloscope (Beaverton, OR). 
The rate of FM 1-43 dye destaining serves as a real-time measure of vesicular glutamate 
release. All control conditions contained AMPA-R and NMDA-R antagonists, NBQX (10 µM) 
and AP-5 (50 µM), in the ACSF superfusion during loading and unloading protocols unless 
otherwise stated. Drugs were applied by superfusion for 10 minutes prior to imaging: D2-R 
agonist (+/-) quinpirole (0.5 µM), D2-R antagonist (S)-sulpiride (10 µM), D1-R agonist SKF 
38393 (10 µM), D1-R antagonist SCH 23390 (10 µM), mGluR1 antagonist CPCOOEt (7-





antagonist bicuculline (5µM), and GABA-B receptor antagonist CGP52432 (1 µM), were 
obtained from Tocris Bioscience, Sigma-Aldrich, and AG Scientific. 
 
Optical Imaging Analysis 
 Fluorescent corticostriatal terminals in the dorsolateral striatum were visualized using a 
Prairie multiphoton laser-scanning microscope equipped with a titanium-sapphire laser 
(excitation 900 nm/emission 625 nm) and a 40x water-immersion objective (Olympus). Images 
were captured in 16-bit, 75.2 x 75.2 µm regions of interest (ROI) at 512 x 512 pixel resolution 
and acquired at 35 second intervals using Prairie View 4.0.0.50 software. To compensate for z-
axis shift, a z-series of five images, separated by 1 µm in the z-axis, was obtained for each 
imaging period. The time series of images was analyzed for changes in presynaptic terminal 
fluorescence using Image J (Wayne Rosband, National Institutes of Health, Rockville, MD) 
(Zakharenko, Zablow et al. 2001, Bamford, Zhang et al. 2004). The criteria for punctum 
inclusion were (1) spherical in shape, (2) fluorescence two standard deviations above the 
background, and (3) stimulation-dependent destaining. Image J aligned and combined the five 
image z-series for each time interval and the Multiple Thresholds plug-in was able to identify 
fluorescent puncta, 0.5-1.5 µm in diameter, in the dorsolateral striatum at time 0 sec, prior to 
destaining stimulation (Figure 2.2 C and Figure 2.4 A). The intensity of the FM 1-43 
fluorescence (excluding identified puncta) was measured over the course of the time series 
(Figure 2.4 B) and Image J was used to subtract background fluorescence of the tissue from the 





puncta fluorescence just prior to application of destaining stimulation (Figure 2.4 C). The 
halftime of fluorescence intensity decay during destaining (t1/2) of each puncta was determined 
using a software algorithm written on SigmaPlot software (SPSS, Chicago, IL). Nearness of fit to 
first-order kinetics was determined using A = 100*EXP (ln(0.5)*t/t1/2), an integrated form of the 
first-order kinetics equation, -d[A]/dt = k[A] (Figure 2.4 D). 
 
 
Figure 2.4. Optical Imaging Analysis. (A) Example of three representative destaining puncta 
identified by ImageJ. (B) Puncta #265 over time. Outlined boxes represent stimulation onset and 
t1/2 of fluorescence destaining. (C) Destaining curves over time of three representative puncta. 
Stimulation begins at t = 0 sec. (D) Calculation of t1/2 value for each puncta determined by fit to 






Values given in the text and in the figures are mean ± SE. Differences in mean values, 
derived from > 4 slices from > 4 mice, were assessed with the non-parametric Mann-Whitney 
test (two groups) or appropriate ANOVAs (multiple groups) followed by multiple comparisons 
using Bonferroni post-tests. For optical studies, population distributions were compared using 
the non-parametric Mann-Whitney test and changes in terminal subpopulations were also 
determined using normal probability plots. The t1/2 kinetics of corticostriatal terminals displayed 
in a probability plot show distribution of t1/2 of individual puncta in each experimental condition 
(y-axis) in relation to standard deviations from median t1/2 (x-axis).  Statistical characteristics of 
each plot are analyzed in separate terciles: fast-releasing terminals (standard deviation: -3 to -1), 
middle-releasing terminals (standard deviation: -1 to +1), slow-releasing terminals (standard 
deviation: +1 to +3) (Yuanjia Wang, PhD, Department of Biostatistics, Columbia University). 
These divisions are necessary as fast-releasing terminals have a high probability of release and 
can be considered “more active”; whereas slow-releasing terminals have a low probability of 
release and can be considered “less active”. The probability plot is used to compare the shapes of 
distributions as well as median t1/2 values of the different populations (fast, middle, and slow) 
and allows a numerical comparison between the scatter of t1/2 values between different subgroups 
of terminals. Differences analyzed by GraphPad Prism were considered significant if p < 0.05. 
For analysis of subgroups in the probability plots, utilization of multiple statistical tests required 
a Bonferroni adjustment. Since three tests were performed per subgroup (fast, middle, and slow), 
as well as one test to examine the overall distribution, the adjusted significance level is 






Aim 1: Are contralateral corticostriatal inputs (IT-type neurons) functionally discrete from 
ipsilateral corticostriatal inputs (both IT-type and PT-type neurons)? 
 
To ensure that distal cortical stimulation is able to activate terminals in the contralateral 
cortex, the stimulating bipolar electrode was sequentially placed along the corticostriatal axon 
pathway. Cortical activity was found to differ when the contralateral cortex (CTX) was intact 
(Figure 2.5) versus removed (Figure 2.6). In slices with the contralateral cortex intact, activity of 
the terminals remains unchanged when the stimulating electrode was placed along the axon 
pathway at positions 5 to 2 (position 5 t1/2 = 276.8 sec; position 4 t1/2 = 267.1 sec; position 3 t1/2 = 
278.5 sec; position 2 t1/2 = 299.3 sec); however, when the stimulating bipolar electrode is placed 
ipsilateral to the terminals imaged, at position 1, corticostriatal activity is enhanced (t1/2 = 233.1 
sec). When reducing the distance between stimulation and imaging regions (from position 5 to 
1), the average number of FM 1-43 destaining puncta per slice had a tendency to increase (31 to 
48). For slices with the contralateral cortex removed, activity of the terminals is unchanged along 
the axon pathway from position 5 to 2 (position 5 t1/2 = 239.5 sec; position 4 t1/2 = 238.5 sec; 
position 3 t1/2 = 252.9 sec; position 2 t1/2 = 229.9 sec). When the stimulating bipolar electrode is 
placed at position 5 and the imaging region is ipsilateral to stimulation (t1/2 = 217.6 sec), activity 
is similar to that of ipsilateral inputs when the contralateral hemisphere is removed (t1/2 = 189.5 









Figure 2.5. Contralateral inputs with both cortices intact. (A) Stimulating electrode placement is 
indicated by numbers 1 to 5 along the axon pathway of contralateral corticostriatal inputs. 
Region of cortical terminals imaged is indicated by the oval in the dorsolateral striatum. (B) 
Electrode placement along the axonal path had no effect on t1/2, except at position 1. (C) Number 
of FM1-43 destaining puncta increased as distance between bipolar stimulating electrode and 









Figure 2.6. Contralateral inputs with contralateral cortex removed. (A) Stimulating electrode 
placement is indicated by numbers 2 to 5 along the axon pathway of contralateral corticostriatal 
inputs. Region of cortical terminals imaged is indicated by the oval in the dorsolateral striatum 
contralateral to stimulation, except in the "Position 5 / Image Ipsil" condition. (B) Electrode 
placement along the axonal path had no effect on t1/2. (C) Number of FM1-43 destaining puncta 
increased as distance between bipolar stimulating electrode and imaging region decreased. (n = 3 
to 15 slices) 
 
To confirm that the terminal activity measured in the contralateral striatum is due to 
contralateral cortical input stimulation, a lesion was made between the hemispheres through the 
corpus callosum (CC transection) following FM1-43 loading (Figure 2.7). No destaining 
occurred upon unloading stimulation. This was similar to destaining rates recorded in the 







Figure 2.7. Contralateral corticostriatal inputs traverse through the corpus callosum. (A) 
Schematic of a lesion between the hemispheres through the corpus callosum (CC transection). 
(B) Unloading stimulation following CC transection (red) did not destain corticostriatal 
terminals. Stimulation begins at t = 0 sec. 
 
Comparing corticostriatal activity of ipsilateral (t1/2 = 189.5 sec) to contralateral (t1/2 = 








Figure 2.8.  Comparison of ipsilateral and contralateral corticostriatal activity. (A) Destaining 
rate of FM1-43 indicates depressed activity of contralateral inputs (blue and red) compared to 
that of ipsilateral (black). Stimulation begins at time = 0 sec. (B) Average t1/2 values confirm an 
increased latency of contralateral input when the contralateral cortex is intact (red) compared to 
when the contralateral cortex is removed (blue). (n = 11 to 17 slices; * p < 0.05, *** p < 0.0001, 
Mann-Whitney test) 
 
The distribution of the terminal activity is represented in a probability plot (Figure 2.9) 
and median values of different populations of terminals are displayed in Table 2.1. Compared to 
ipsilateral terminals (black), contralateral terminals have depressed release kinetics among all 
three populations of terminals (Figure 2.9 B to D). Increased depression of activity of all 







Figure 2.9. Ipsilateral and contralateral normal probability. (A) Normal probability plots 
characterize the individual puncta following 10 Hz stimulation. Contralateral inputs display 
depressed activity with the cortex removed (blue)  and with the cortex intact (red), but maintain 
similar distributions of terminal release profiles compared to ipsilateral inputs (black). (B to D) 








Table 2.1. Median values of ipsilateral and contralateral activity. Depressed activity of 
contralateral inputs in all populations (n > 11 slices). 
 
Pharmacological evaluation of possible inhibitory influences on corticostriatal terminals 
was performed to verify that the depressed activity of contralateral inputs was characteristic of 
the baseline activity of these inputs (Figure 2.10). A variety of receptors have been identiﬁed at 
both glutamatergic and GABAergic synapses in the striatum that are linked to presynaptic 
inhibition of neurotransmitter release: cannabinoid (CB1), GABA-B, muscarinic and 
metabotropic glutamate (mGLU) receptors has been shown to inhibit glutamatergic synaptic 
transmission in the striatum through presynaptic mechanisms (Sugita, Uchimura et al. 1991, 
Lovinger and McCool 1995, Pisani, Calabresi et al. 1997, Malenka and Nicoll 1998, Gerdeman 
and Lovinger 2001, Calabresi, Picconi et al. 2007). 
The mGLU-Rs located on the postsynaptic terminals could be activated by high 
frequency cortical stimulation. The mGLU-R 1 antagonist, CPCOOEt (CPC; 40 µM), however, 
did not alter destaining or t1/2 of contralateral terminal activity. GABA-A receptors and GABA-B 
receptors localized in the striatum could also provide inhibitory effects on corticostriatal activity. 





µM), did not alter destaining or t1/2 of contralateral terminal activity. Additionally, in the absence 
of blockers, including the control blockers of AMPA-R (NBQX; 10 µM) and NMDA-R (AP-5; 
50 µM), contralateral destaining and t1/2 of terminal activity remained unchanged. Therefore, we 
concluded that the depression of contralateral corticostriatal activity compared to that of 




Figure 2.10. Latency contralateral activity is not pharmacologically altered. (A) Destaining rate 
of FM1-43 activity did not change with CPCOOEt (purple; CPC; 40 µM), removal of all 
blockers (grey), bicuculline (yellow; BIC; 5 µM), or CGP52432 (orange; CGP; 2 µM). (B) 







 One explanation of the slower presynaptic activity of contralateral inputs is that 
antidromic stimulation could result in depressed corticostriatal activity when the contralateral 
cortex is intact (Figure 2.11). Previous studies of IT neurons determined that a small subset 
targets both striata as well as the contralateral cortex (Wilson 1987). Stimulation of the cortex 
(Figure 2.11; right hemisphere) could activate IT neurons located in the contralateral cortex 
(Figure 2.11; left hemisphere) that also send ipsilateral projections to the striatum where imaging 
was conducted. We previously correlated depressed activity with increased distance between 
stimulation and imaging regions (Figure 2.5 and 2.6). This increase in distance via indirect 
antidromic stimulation could be a source of increased latency of contralateral inputs when the 
contralateral cortex is intact.  To avoid corticostriatal activation via antidromic stimulation, all 
subsequent experiments were performed with the contralateral cortex removed. 
 
 
Figure 2.11. Antidromic stimulation of contralateral corticostriatal input. (A) Schematic of the 
contralateral cortical input activation. Stimulation placed in the cortex of the right hemisphere is 
shown by the bipolar electrode. Imaging region in the contralateral (left) striatum is shown by the 






 The effect of DA release on the activity of excitatory corticostriatal inputs was assessed 
in the presence of DA D1 and D2 receptors agonists and antagonists. Drugs were superfused 
onto the slice prior to unloading stimulation (Figure 2.12). For both ipsilateral and contralateral 
corticostriatal inputs, the D2-R agonist, quinpirole, induced a marked depression of terminal 
activity. All other drugs tested did not have any effects on corticostriatal activity. 
 
 
Figure 2.12. D1-R and D2-R effects on ipsilateral and contralateral activity. (A) Mean t1/2 ± 
SEM values of ipsilateral cortical inputs were decreased in the presence of D2-R agonist, 
quinpirole (Quin). There was no change in activity in the presence of D1-R agonist, SKF38393 
(SKF) and antagonist, SCH23390 (SCH) or D2-R antagonist, sulpiride (Sul). (B) Average t1/2 
values of contralteral cortical inputs were decreased in the presence of quinpirole. There was no 
change in activity in the presence of D1-R agonist and antagonist or D2-R antagonist. (n = 4 to 






The effects of D2-R agonists and antagonists on the distributions of the ipsilateral (Figure 
2.13) and contralateral (Figure 2.14) terminal activity are represented in normal probability plots 
and median values of different populations of terminals displayed in Table 2.2. Compared to 
control conditions (grey), in the presence of quinpirole, a D2-R agonist, ipsilateral terminals 
show a significant depression of release kinetics in the slow-releasing terminals. No effect was 
identified among the three populations from the D2-R antagonist, sulpiride. 
 
 
Table 2.2. Median values of D2-R effects on ipsilateral and contralateral activity. D2-R 








Figure 2.13. D2-R effects on ipsilateral normal probability plots. (A) Ipsilateral inputs in control 
conditions (grey) displayed similar release profiles in the presence of sulpiride (green; open 
circles). The terminal activity distribution was slowed in the presence of quinpirole (green; 
closed circles). (B) No difference was identified in fast-releasing terminals. (C to D) Quinpirole 
induced a strong depression of activity in middle- and slow-releasing terminals (n = 5 to 11 







Figure 2.14. D2-R effects on contralateral normal probability plots. (A) Contralateral inputs in 
control conditions (grey) showed similar release profiles in the presence of sulpiride (green; open 
circles). Terminal activity distribution was slowed in the presence of quinpirole (green; closed 
circles). (B) No difference was identified among conditions in fast-releasing terminals. (C to D) 
Quinpirole induced a depression of activity in middle- and slow-releasing terminals (n = 4 to 15 






Aim 1: Are contralateral corticostriatal inputs (IT-type neurons) functionally discrete from 
ipsilateral corticostriatal inputs (both IT-type and PT-type neurons)? 
 
 We adapted multiphoton confocal microscopy and destaining of the endocytic tracer FM 
1-43 to measure corticostriatal terminal activity in ipsilateral and contralateral cortical inputs. 
Targeting corticostriatal neurons (stimulation in cortical layer V and imaging in the dorsolateral 
striatum) while loading and unloading FM 1-43 ensured specific identification of labeled 
terminals. Specific labeling of contralateral inputs were consistent with the observation that 
stimulation of various points along the axon pathway along the corpus callosum did not change 
the destaining kinetics or the average t1/2 values. Additionally, corpus callosum transection 
prevented unloading of FM 1-43 in contralateral inputs.  
FM 1-43 destaining experiments showed contralateral corticostriatal inputs had slower 
release kinetics than ipsilateral projections. This observation is consistent with previous 
functional studies of corticostriatal neurons also reporting an increased latency of contralateral IT 
inputs using EPSP recordings (Cowan and Wilson 1994, Ballion, Mallet et al. 2008). Release 
kinetics were further inhibited when the contralateral cortex remained intact. 
Pharmacological analysis of possible inhibitory effectors on corticostriatal inputs in the 
striatum (mGLU-Rs, GABA-A Rs, and GABA-B Rs) also did not alter the destaining kinetics or 
the average t1/2 values. Additionally, since all experimental conditions contained antagonists of 





cortical stimulation. We therefore conclude that the depressed activity of contralateral inputs can 
be attributed to a physiological characteristic of the inputs themselves. When the contralateral 
cortex is intact, stimulation of the cortex is able to antidromically stimulate axons with cell 
bodies in the contralateral cortex and activate these inputs. This increased distance between 
electrical stimulation and terminals could account for depressed activity.  
 Contralateral inputs to the striatum are solely composed of IT neurons, whereas 
ipsilateral inputs are composed of both IT and PT neurons (Wilson 1987, Flaherty and Graybiel 
1991, Cowan and Wilson 1994, Reiner, Jiao et al. 2003, Sohur, Padmanabhan et al. 2012). 
Presynaptic terminal activity of ipsilateral and contralateral corticostriatal inputs is functionally 
analogous, as determined by FM 1-43 destaining experiments. This is supported by 
electrophysiological evidence that IT neurons may provide the main excitatory input as the PT 
input was found to be much weaker (Ballion, Mallet et al. 2008); and by morphological evidence 
that striatal collaterals of PT neurons make sparse en passant arborizations in the striatum, 
whereas IT neurons have a more extensive arborization pattern in dense clusters within the 
striatum (Cowan and Wilson 1994, Reiner, Jiao et al. 2003, Parent and Parent 2006). The 
presynaptic cortical activity visualized by FM 1-43 (here) and measured by electrophysiology 
(previously) are in agreement that the corticostriatal inputs on both the ipsilateral and 
contralateral sides are functionally similar. Due to extensive arborizations in the striatum, IT 
neurons may have represented a majority of the terminals measured in our imaging studies. 
Therefore, IT and PT neurons may be functionally discrete, but more specific experimentation 





Effects of the D2-R agonist quinpirole on ipsilateral and contralateral inputs also reveal 
similar characteristics. The presence of presynaptic D2-Rs on corticostriatal axon terminals is 
supported by anatomical (Sesack, Aoki et al. 1994, Wang and Pickel 2002) and 
electrophysiological (Hsu, Huang et al. 1995, Flores-Hernandez, Galarraga et al. 1997, Cepeda, 
Hurst et al. 2001) evidence. D2-Rs provide a high-pass "filter" for corticostriatal synaptic 
terminal activities via presynaptic inhibition as shown previously (Bamford, Robinson et al. 
2004, Bamford, Zhang et al. 2004, Bamford, Zhang et al. 2008, Wang, Dever et al. 2012). With 
quinpirole, the most active (fast-releasing) corticostriatal inputs are unaffected while the activity 
of the less active (slow-releasing) inputs with low probability of release is selectively inhibited. 
This “filtering effect” of D2 receptors has been shown here for the first time to be present on 
contralateral IT neurons. In terms of motor command signaling, DA release interacts with a 
highly activated cortical input during motor learning to reinforce specific subsets of 
corticostriatal connections. 
Together, the data suggest that ipsilateral and contralateral cortical inputs are functionally 
similar, aside from a slight depression in overall activity. Both types of cortical inputs show 
analogous high-pass filtering of activity in the presence of quinpirole. The role of DA on cortical 






Dopamine Influence on Corticostriatal Inputs 
 
Introduction 
 In this chapter, we explore the role of chronic dopamine (DA) depletion on the 
presynaptic activity of ipsilateral and contralateral corticostriatal projections. In PD, motor 
dysfunction results from loss of the dopaminergic input to the striatum, resulting in an imbalance 
of the basal ganglia outflow and an inability to move effectively in response to motor commands. 
To explore how the lack of DA input will influence corticostriatal activity and contribute to loss 
of motor function, we will use the 6-OHDA mouse model of PD to study the synaptic changes 
that result from chronic DA depletion. 
 
Effects of DA Depletion on the Striatal Microcircuit 
 Electron microscopy studies of reserpine-treated (acute DA depletion) mice, indicate that 
DA depletion leads to a rapid and profound loss of dendritic spines and asymmetric densities that 
contact those spines, specifically in the striatopallidal indirect pathway MSNs (Day, Wang et al. 
2006). These asymmetric densities are characteristic of glutamatergic synapses formed by 
corticostriatal inputs. The authors suggested that the loss of D2 receptor tone following DA 
depletion disinhibits Cav 1.3 L-type Ca2+ channels that underlies the destabilization of spines and 
synaptic contacts. These same studies confirmed that physiological activity of glutamatergic 
synapses on striatopallidal neurons were reduced to roughly half after DA depletion (Day, Wang 





OHDA lesion showed changes in corticostriatal glutamate density depending on the degree of 
DA loss (Meshul 1999; Meshul and Allen 2000; Robinson 2001, 2003). 
 In addition to morphological alterations in spines following DA depletion, 
electrophysiological studies have suggested that in conditions of DA denervation, there is a 
hyperactivity of corticostriatal glutamatergic transmission (Lindefors and Ungerstedt 1990, 
Calabresi, Mercuri et al. 1993, Campbell and Bjorklund 1994, Calabresi, Centonze et al. 2000) 
with increased numbers of striatal neurons responding to cortical stimulation (Florio, Di Loreto 
et al. 1993). Some electrophysiological studies have also reported that 6-OHDA treatment 
selectively depresses the activity of IT neurons, while PT neurons are not affected (Mallet, 
Ballion et al. 2006, Ballion, Mallet et al. 2008). In general, unilateral DA denervation causes loss 
of corticostriatal synaptic plasticity (Calabresi, Centonze et al. 2000). Previous optical studies in 
the Sulzer and Bamford labs (Bamford, Robinson et al. 2004, Bamford, Zhang et al. 2004) 
suggest that these changes in cortical activity are a result of an elimination of DA "filtering" 
effect on cortical inputs. However, these optical studies were performed in mice with dopamine-
deficiency (developmental loss of DA) and in mice that were treated with reserpine, (acute loss 
of DA). The effects following long-term DA depletion on presynaptic cortical inputs have not 









Behavioral Effects of D1 and D2 Receptors 
 In WT rodents, administration of selective D1 or D2 agonists induces behaviors such as 
grooming (D1) or locomotor and exploratory behavior (D2), while administration of the mixed 
D1/D2 agonist, apomorphine (APO), elicits a sequence of motor activities which can be blocked 
by D1 antagonists (Morelli, Fenu et al. 1991). This is suggestive of a complex interaction 
between the two receptors and that simultaneous D1 and D2 receptor stimulation is necessary for 
the full expression of DA-mediated effects in the basal ganglia. 
The roles of D1 and D2 receptors in motor movement have been dissected by the 
Palmiter group using DA–deficient (DD) mice (Kim, Szczypka et al. 2000). DD mice are devoid 
of DA during development due to targeted deletion of the tyrosine hydroxylase gene in DA 
neurons (Zhou and Palmiter 1995, Bamford, Robinson et al. 2004). DD mice displayed enhanced 
locomotion in response to either the D1-R agonist SKF 81297 or D2-R agonist quinpirole (Kim, 
Szczypka et al. 2000).  
In unilateral 6-OHDA lesioned rodents, asymmetric circling behavior can be induced by 
administration of amphetamine (AMPH) or APO. AMPH increases extracellular DA in part 
through non-vesicular release and induces ipsiversive circling behavior (away from the side of 6-
OHDA injection), whereas APO, a nonspecific D1 and D2 receptor agonist, induces 
contraversive circling behavior (away from the side of 6-OHDA-injection) (Ungerstedt 1968, 
Arnt and Hyttel 1986, Brannan, Prikhojan et al. 1998). This is because AMPH circling is 
mediated by release of DA and subsequent receptor stimulation of DA receptors in the intact side 
of the brain whereas direct DA agonists and APO exhibit circling in the opposite direction as a 





Herrera-Marschitz et al. 1982). A synergistic action of D1 and D2 receptor agonists was 
proposed by studies that determined administration of either D1 or D2 antagonists abolished 
contraversive circling induced by APO (Arnt and Hyttel 1986).  The contribution of D1 and D2 
receptor activation in motor behavior has not been clearly defined despite a multitude of animal 
models and study parameters employed over the years. 
 
Corticostriatal Inputs and D2-Rs  
 Previous studies have demonstrated that glutamate release from corticostriatal fibers is 
regulated by striatal DA including by D2 receptors located on corticostriatal terminals (Maura, 
Giardi et al. 1988, Garcia-Munoz, Young et al. 1991, Calabresi, Mercuri et al. 1993, Hsu, Huang 
et al. 1995, Tang and Lovinger 2000, Bamford, Robinson et al. 2004, Bamford, Zhang et al. 
2004). In Aim 1 (Chapter 2) of this thesis, we demonstrated this ability of D2-R activation to 
induce inhibitory filtering effects is present on both ipsilateral and contralateral corticostriatal 
inputs. How presynaptic cortical activity is affected following chronic DA depletion via 6-
OHDA lesion and the subsequent response to D2-R activation are explored in Aim 2 (Chapter 3). 
Following DA denervation by 6-OHDA, studies report enhanced sensitivity of 
presynaptic inhibitory D2-like receptors and abnormal striatal glutamatergic excitatory 
transmission (Picconi, Paille et al. 2008). This effect reflects the loss of D2-R meditated control 
of corticostriatal transmission (Cepeda, Hurst et al. 2001), and can also be explained by an 
upregulation of D2-Rs as well as receptor supersensitivity and eCB retrograde signaling (Di 





FM 1-43 in DA-deficient (DD) mice and reserpine-treated mice (Bamford, Robinson et al. 2004). 
In DD mice, activation of D2-Rs induces an inhibition of ipsilateral glutamatergic transmission 
to a greater extent than in control mice and there was a dose-dependent depression of cortical 
activity (Bamford, Robinson et al. 2004). Similar findings were reported in mice with acute DA 
depletion due to reserpine treatment. Enhanced inhibition of corticostriatal activity by D2-Rs is 
supported by other groups reporting that inhibition following quinpirole treatment is coupled to 
an increase in paired-pulse facilitation (Picconi, Paille et al. 2008, Tozzi, de Iure et al. 2011), and 
that quinpirole reduces the frequency of spontaneous EPSCs, both of which are 
electrophysiological measures of presynaptic effects. This presynaptic D2-mediated inhibitory 
effect on cortical inputs has been proposed to result from either a direct presynaptic modulation 
of D2-Rs (Maura, Giardi et al. 1988, Bamford, Robinson et al. 2004, Bamford, Zhang et al. 
2004) and/or a retrograde D2-R signal of cannabinoid release from MSNs (Yin, Davis et al. 










Figure 3.1. Model of Parkinson’s disease mediated changes in the synaptic microcircuit. (A) 
During normal motor signaling, D2-Rs (blue) play an active role in regulating glutamate (pink) 
release from corticostriatal input. (B) In DA depleted state, DA D2-Rs become supersensitive 
and glutamate release may increase due to reduced DA availability following loss of substantia 
nigral dopaminergic input.  
 
CB1-Rs 
 In addition to the direct effect of presynaptic D2-R regulation of corticostriatal activity, 
D2-CB1-R co-activation provides an indirect mechanism to negatively regulate striatal excitatory 
transmission (Herkenham, Lynn et al. 1991, Meschler and Howlett 2001). Several studies have 
shown that stimulation of D2-Rs on the postsynaptic striatopallidal MSNs can rapidly synthesize 
and increase levels of striatal endocannabindoid (eCB), anandamide (AEA), which may serve as 





1999, Beltramo, de Fonseca et al. 2000, Ferrer, Asbrock et al. 2003). This retrograde 
transmission from D2-R to activate CB1-Rs reduces glutamate release in the striatum through a 
presynaptic mechanism via corticostriatal inputs (Gerdeman and Lovinger 2001, Wang, Dever et 
al. 2012). In corticostriatal terminals, presynaptic CB1-Rs regulate the release and uptake of 
glutamate, and thereby lead to reduction of glutamate-mediated excitation in MSNs (Brown, 
James et al. 1990, Gerdeman and Lovinger 2001, Gubellini, Picconi et al. 2002). However, 
postsynaptic CB1-Rs by coupling to different types of G proteins have different modulatory 
effects on D1 and D2-mediated responses, acting as negative and positive modulation of MSNs, 
respectively (Meschler and Howlett 2001). 
In the 6-OHDA lesioned and reserpine-treated rodent models of PD, overactivity of eCB 
transmission is reported by multiple studies that found increased tissue levels of eCBs 
(specifically AEA, not 2-AG), increased CB1-R mRNA, downregulation of both AMT 
(anandamide membrane transporter) and FAAH (fatty acid amide hydrolase) which catalyzes the 
breakdown of AEA, and increased AEA tone (Mailleux and Vanderhaeghen 1993, Romero, 
Berrendero et al. 2000, Gubellini, Picconi et al. 2002, Fernandez-Espejo, Caraballo et al. 2005, 
Gonzalez, Scorticati et al. 2006). In general, the majority of previous studies suggest that 
increased AEA tone results in an overactive eCB system in the BG in PD. A few studies, 
however, report a reduction in eCB activity (Silverdale, McGuire et al. 2001) and decreased 
AEA tone (Ferrer, Asbrock et al. 2003, Kreitzer and Malenka 2007, Morgese, Cassano et al. 
2007). The reason for these contradictory reports is not clear. 
 The enhanced CB1-R signaling in the striatum is often viewed as an attempt of the DA-





of CB1-R signaling and reduction of striatal glutamate release might alleviate symptoms of PD 
(Gerdeman and Lovinger 2001, Gubellini, Picconi et al. 2002). However, enhanced CB1-R 
signaling functioning on the GPe, can enhance GABA transmission, leading to inhibition of GPe 
and contribute to the symptoms of PD (Brotchie 2003). In other words, CB1-R antagonism has 
the potential to alleviate or exacerbate parkinsonian symptoms depending on its target of action. 
Taken together, corticostriatal alterations following loss of DA may contribute to motor 
dysfunction. The state of DA depletion that causes abnormal corticostriatal excitatory activity 
and loss of motor control is addressed in the following aim: 
 
Aim 2. How does chronic unilateral ablation of dopamine affect corticostriatal activity? 
(a) Ipsilateral corticostriatal inputs 





For these experiments, we chose to use 6-OHDA mice with unilateral intrastriatal lesions. This 
mouse model serves as a good representation of varying stages of PD as severity of lesion can 
easily be controlled by dose of 6-OHDA (Przedborski, Levivier et al. 1995). Since DA neuron 
degeneration is progressive, this model is representative of the slow and protracted DA loss in 





we will explore in Chapter 4. Additionally, by injecting the neurotoxin into the dorsal striatum at 
the DA terminals, the retrograde lesion corresponded to specific loss of dopaminergic SNc cell 
bodies with minimal damage to the VTA and its projection area, negligible amount of gliosis at 
the site of injection and preserved the gross anatomy of the striatum (Przedborski, Levivier et al. 
1995). As injections were made unilaterally, the sensorimotor behaviour of the contralateral side 
of the body is affected, but the animal was still able to eat and drink and care for themselves 
(Robinson, Krentz et al. 2001, Cenci and Lundblad 2007). Thirty minutes prior to 6-
hydroxydopamine (6-OHDA, Regis Technologies) infusion, mice were injected with 
desipramine (15 mg/kg, i.p.) to protect noradrenergic terminals from 6-OHDA toxicity. Mice 
were anesthetized with ketamine/xylazine (1:1:4, 0.15-0.20 mL, i.p.) and positioned in a Kopf 
stereotaxic apparatus. A midline scalp incision is made, a burr hole (AP: +0.9, ML: +2.2 mm 
from bregma) is marked, and a hole drilled with a Dremel tool. Saline solution (0.9%) containing 
0.2% ascorbic acid to avoid oxidation was used to dissolve 6-OHDA (5 mg/mL) immediately 
prior to infusion and attached to a mini-pump. A cannula was inserted into the striatum at AP: 
+0.9 mm; ML: +2.2 mm; DV: -2.5 mm in relation to dura. 6-OHDA solution was infused at 0.5 
µl/min for 6 min (total dose: 15 µg). The cannula was left in place for 5 minutes at the end of the 
infusion to prevent backflow and reduce intracranial pressure before being slowly withdrawn. 
Sham-injected control mice followed the same protocol except that the injected solution lacked 
6-OHDA. After the application of 6-OHDA or saline, mice were allowed to recover for 3 weeks 







FM 1-43 Imaging 
 See Chapter 2 for methods. Additionally, all control conditions contained AMPA-R and 
NMDA-R antagonists, NBQX (10 µM) and AP-5 (50 µM), as well as the mGluR1 antagonist 
CPCOOEt (40 µM) in the ACSF superfusion during loading and unloading protocols unless 
otherwise stated. Drugs were applied by superfusion for 10 minutes prior to imaging: (+/-) 
quinpirole (D2-R agonist; 0.5 µM), (S)-sulpiride (D2-R antagonist; 10 µM), AM251 (CB1-R 
antagonist; 2 µM), WIN-55 212-2 (CB1-R agonist; 1 µM) were obtained from Tocris 
Bioscience, Sigma-Aldrich, and AG Scientific. 
 
Behaviour Tests 
 Drug-induced rotation has been the predominant behavioural test for studying rodent 
models of PD. However, it is often not an accurate indicator of dopaminergic deficit nor a 
reliable predictor of therapeutic efficacy (Schallert, Fleming et al. 2000). Since sensorimotor 
inputs from the cortex project to the dorsolateral striatum (Figure 1.2 D), unilateral DA depletion 
in the dorsolateral striatum causes chronic deficits in somatosensory function and use of the 
contralateral forelimb (Schallert, Fleming et al. 2000, Schallert 2006). Forelimb use asymmetries 
were reliably quantified in the cylinder and corridor tests (Figure 3.2). Behaviour tests were 
performed 3 weeks following 6-OHDA intrastriatal lesion when dopaminergic cell loss and 
striatal terminal degeneration is maximal (Jeon, Jackson-Lewis et al. 1995, Przedborski, Levivier 






Figure 3.2. Experimental time line. Three weeks following unilateral 6-OHDA stereotaxic 
injection, cylinder and corridor behaviour tests were performed to evaluate lateralized motor 
behaviour (Grealish, Mattsson et al.). Optical experiments using FM 1-43 measured presynaptic 
corticostriatal activity. Quantification of extent of lesion was confirmed by western blot analysis 
of the dorsal striatum and location of DA lesion was confirmed by immunohistochemistry.  
 
With the cylinder test (Schallert, Fleming et al. 2000, Lundblad, Andersson et al. 2002, 
Picconi, Centonze et al. 2003), forelimb use asymmetry was tested on one occasion to assess 
DA-dependent explorative activity when a mouse is placed individually in a novel transparent 
cylinder for 5 minutes. The number of supporting wall contacts executed by the right and left 
paw during a rearing behaviour are counted offline. With the corridor test (Grealish, Mattsson et 
al. , Dowd, Monville et al. 2005), a mouse was placed individually in a corridor apparatus with 





testing, the mouse was habituated to the corridor apparatus, food-restricted (1.5 g/day), and 
introduced to the sugar pellets involved in this behaviour test. On the day of testing, the mouse 
was placed in the corridor for 10 minutes and DA-dependent sensorimotor behaviour of 
retrieving sugar pellets from the left and right sides was counted over 10 minutes. 
 Previous studies using forelimb akinesia tests (cylinder and corridor tests) have 
determined a correlation between the extent of DA lesion with the severity of motor 
lateralization (Figure 3.3).  
 
Figure 3.3. Correlation between the extent of DA depletion and lateralized behavior (Grealish, 
Mattsson et al. 2010). (A) Using immunohistochemistry for tyrosine hydroxylase (TH), the 
extent of DA depletion was categorized as severe lesion (88.8%; top), intermediate lesion 
(69.1%; middle) and mild lesion (43.1%; bottom). (B) Correlation of striatal denervation with 





Therefore, following FM experiments, western blot analysis (Figure 3.4) of the dorsal 
striatum was performed to confirm loss of dopamine transporter (DAT) and tyrosine hydroxylase 
(TH) in the DA lesioned and intact hemispheres. 
 
Western Blot 
 Following optical experiments, the dorsal striatum was removed from both hemispheres 
of each slice (Figure 3.4 A) and sonicated in 75 µL of 1% SDS. Protein concentration was 
determined by the BCA method (Pierce). A total of 15 µg were loaded in each well of a 15% 
bisacrylamide gel and run at 180 mV for 1 hour or until protein ladder markers (Fisher) were 
well separated. Protein was transferred to a PVDF membrane at 40 mV for 3 hours or at 10 mV 
overnight. Membranes were then washed in 1x TBS/0.05% Tween-20, blocked in 5% milk and 
incubated with primary antibodies: 1:1000 anti-rat DAT (Millipore), 1:5000 anti-mouse TH 
(Millipore) and 1:10000 anti-mouse β-actin. Corresponding HRP-conjugated goat secondary 
antibodies were used at a 1:10000 concentration; anti-mouse (Thermoscientific), anti-rat 
(Novus). Protein was detected by incubating membranes for 5 minutes with HRP substrate 
(Millipore), and Image J was used to determine the intensity of bands using β-actin to normalize 
the signal. Data in Figure 3.4 present average of mean and SEM of signal intensity of the DA-






Figure 3.4. Quantification of DA depletion by western blot analysis. (A) Following optical 
experiments, the dorsal striatum was removed from both hemispheres of each slice and processed 
for western blot (WB) analysis. (B) Representative western blot of DAT (70-85 kDa), TH (56-60 
kDa), and the protein loading control β-actin (45 kDa) from matched slices of injected (6-OHDA 




 To confirm consistency of 6-OHDA sterotaxic injections, immunohistochemistry of mice 
not used for FM 1-43 imaging experiments was performed to confirm localization of DA lesion 





(1:1:4, 0.15-0.20 mL, i.p.), and perfused with 4% paraformaldehye in 1x phosphate buffer 
solution (PBS). Mice were decapitated and brains carefully removed, embedded in O.C.T 
compound for preservation at -80ºC. Coronal brain sections (30 µm thick) were cut on a cryostat 
and collected in PBS. Sections were washed in PBS with 0.1% Triton X-100 (PBS-T) three times 
and incubated in 10% normal goat serum in PBS-T for 60 minutes. Sections were incubated with 
primary antibody, 1:1000 anti-rat DAT (Millipore), in 2% normal goat serum in PBS-T for 1 
hour at room temperature or overnight at 4ºC. Sections were washed in PBS-T four times for 30 
minutes per wash and incubated with secondary antibody, goat anti-rat IgG (1:1000) in PBS-T 
with 2% normal goat serum for 30 minutes. Sections were then washed four times in PBS and 









Figure 3.5. Localization DA depletion confirmed by immunohistochemistry. (A) Serial coronal 
sections of DAT staining in the DA intact hemisphere. Anterior (top left) to posterior (bottom 
right). (B) Serial coronal sections of DAT staining in the DA lesioned hemisphere confirmed DA 
depletion specifically in the dorsal striatum. Anterior (top left) to posterior (bottom right) 







Aim 2a. How does chronic dopamine depletion affect ipsilateral corticostriatal activity? 
 Three weeks following 6-OHDA lesion, forelimb akinesia behavior tests were performed 
to assess the extent of DA lesion (Figure 3.6) immediately prior to FM 1-43 imaging 
experiments. Cylinder tests showed that 6-OHDA injected mice exhibited increased left limb use 
(65.7%) compared to sham injected littermates (50.6%). Corridor tests showed that 6-OHDA 
injected mice had a 94.5% left retrievals compared to saline injected littermates with 50.4% left 
retrieval. Although there appears to be a decreased lateralization severity in the cylinder test, this 
can be explained by the observation that the mouse initiated rearing with the left forelimb but 
tended to use its right forelimb as balance during the rearing behavior. Therefore, the severity of 
lateralization behavior was not as rigorous in the cylinder test compared to the corridor test, but 
results were similar to previous studies using this test (Schallert, Fleming et al. 2000, Picconi, 






Figure 3.6. Lateralized forelimb behavior following 6-OHDA injection. (A) Schematic of 
cylinder (top) and corridor (bottom) tests used to assess lateralized motor behaviour (Grealish 
2010). (B) Cylinder test of 6-OHDA injected mice (black squares) exhibited left limb use 
preference compared to saline-injected littermates (white circles) which showed no preference. 
(C) Corridor test of 6-OHDA injected mice (black squares) had left retrieval preference 
compared to saline-injected littermates (white circles) which again showed no preference. 
 
Baseline corticostriatal activity was determined by FM 1-43 optical experiments (Figure 
3.7) after confirmation of DA-depleted lateralized behavior. Following chronic DA depletion, 
ipsilateral corticostriatal activity in the lesioned hemisphere (t1/2 = 282.7 sec) was slightly 
depressed compared to the intact hemisphere of the same animals (t1/2 = 266.6 sec) and saline-






Figure 3.7. Ipsilateral corticostriatal activity following chronic DA depletion. (A) Schematic of 
ipsilateral inputs: 6-OHDA-lesioned hemisphere (left) and DA intact hemisphere (right). (B) No 
significant change in average t1/2 of each condition. (C) No change in overall destaining curve of 
FM 1-43 (n = 6 to 8 slices). 
 
The distributions of the ipsilateral inputs from saline and 6-OHDA injected animals are 
represented in normal probability plots (Figure 3.8) and median values of different populations 
of terminals displayed in Table 3.1. Compared to sham, ipsilateral terminals of the lesioned 
hemisphere exhibited depression of release kinetics in the slow-releasing terminals. No change 







Figure 3.8. Chronic DA depletion effects on ipsilateral probability plots. (A) Ipsilateral inputs in 
sham controls (white circles) had similar release profiles to ipsilateral inputs in the intact 
hemisphere of 6-OHDA injected animals (grey circles). However, slight differences in the shape 
of terminal activity distribution were seen in the lesioned hemisphere of 6-OHDA injected 
animals (black squares). (B to C) No difference in fast- and middle-releasing terminals. (D) 
Ipsilateral inputs in the lesioned hemisphere of 6-OHDA injected animals (black) had depressed 








Table 3.1. Median values of ipsilateral activity. Depressed activity of ipsilateral inputs to the DA 
lesioned hemisphere in slow-releasing population of terminals (n = 6 to 8 slices). 
 
Effects of D2-R activation by quinpirole were assessed in ipsilateral corticostriatal 
terminals in the lesioned and intact hemispheres (Figure 3.9; green). Quinpirole depressed 
corticostriatal activity in the intact hemisphere (t1/2 = 347.9 sec) and further inhibition was seen 
in the lesioned hemisphere (t1/2 = 386.5). To assess the role of CB1-R inhibition via retrograde 
eCB release from postsynaptic D2-Rs, CB1-R antagonist, AM251, was superfused onto the slice 
in addition to quinpirole (Figure 3.9; blue). In both the intact and lesioned hemispheres, addition 
of AM251 ameliorated the inhibition induced by quinpirole alone. In the intact hemisphere (t1/2 = 
312.7 sec), this was not significantly different from control or quinpirole conditions. However in 
the lesioned hemisphere (t1/2 = 322.5 sec), the effect of CB1-R anatagonism was significantly 







Figure 3.9. D2-R activation of ipsilateral inputs following chronic DA depletion. (A) Ipsilateral 
inputs in the lesioned striatum had significantly depressed average t1/2 values in the presence of 
quinpirole (green) compared to control (grey) and quinpirole + AM251 (blue).  (B) Ipsilateral 
inputs in the intact striatum had significantly depressed average t1/2 values in the presence of 
quinpirole (green) compared to control (grey) (n = 4 to 8 slices; * p < 0.0001, ANOVA 
Bonferroni). 
 
The distributions of the ipsilateral inputs from intact (Figure 3.10) and lesioned (Figure 
3.11) hemispheres of 6-OHDA injected animals are represented in normal probability plots, and 
median values of different populations of terminals displayed in Table 3.2. In the intact 
hemisphere, the inhibitory effect of quinpirole (Figure 3.10; green) was marginal in the middle-
releasing population, but inhibition was very pronounced slow-releasing population. This 
confirms previous findings in Chapter 2 as well as in other studies (Bamford, Robinson et al. 
2004, Bamford, Zhang et al. 2004), of D2-associated “filtering effect” in which D2 activation 
selectively inhibits terminals with lower release probability (slow-releasing terminals). The 





middle- and slow-releasing terminals but to a lesser extent than quinpirole alone. In the lesioned 
hemisphere, a pronounced inhibitory effect of quinpirole (Figure 3.11; green) was seen among 
all populations. The addition of AM251 with quinpirole (Figure 3.11; blue) ameliorated the 
inhibitory effect of quinpirole in all populations - especially the fast- and slow-releasing 
terminals. The D2-associated “filtering effect” that was lost in the lesioned hemisphere was 




Table 3.2. Median values of D2-R effects on ipsilateral activity after DA depletion. D2 
activation by quinpirole selectively inhibited terminals with lower release probability in DA 
intact hemisphere. On the DA lesioned hemisphere, quinpirole inhibited all terminals, and 
addition of the CB1-R antagonist AM251 (Quin + AM) restored the selective inhibition (the 







Figure 3.10. D2-R effects on ipsilateral inputs of the DA intact hemisphere. (A) Differences in 
the distribution of terminal activity between ipsilateral inputs in controls (grey), in the presence 
of quinpirole (green), and quinpirole + AM251 (blue).  (B) No change in fast-releasing terminals. 
(C to D) Inhibitory effect of quinpirole (green) was ameliorated by quinpirole + AM251 (blue) 







Figure 3.11. D2-R effects on ipsilateral inputs of the DA lesioned hemisphere. (A) Differences 
in the distribution of terminal activity between ipsilateral inputs in controls (grey), in the 
presence of quinpirole (green), and quinpirole + AM251 (blue).  (B to D) Significant inhibition 
of all populations with quinpirole (green) is ameliorated by addition of AM251 with quinpirole 
(blue); especially in the fast- and slow-releasing populations of terminals (n = 6 to 8 slices; ** p 





To confirm the inhibitory effect of CB1-Rs, we next compared the effects of D2-R 
activation by quinpirole and CB1-R activation by WIN55. The distributions of the ipsilateral 
inputs from intact (Figure 3.12) and lesioned (Figure 3.13) hemispheres of 6-OHDA injected 
animals are represented in normal probability plots, and median values of different populations 
of terminals displayed in Table 3.3. In both the intact and lesioned hemispheres, the inhibitory 
effect of WIN55 (purple) was the same as that described previously with quinpirole (green). 
 
 
Table 3.3. Median values of D2-R and CB1-R activation on ipsilateral activity after DA 
depletion. Activation of D2-R by quinpirole and CB1-R by WIN55 selectively inhibited 
terminals with lower release probability in DA intact hemisphere. On the DA lesioned 










Figure 3.12. D2-R and CB1-R activation on ipsilateral inputs of the DA intact hemisphere. (A) 
Differences in the distribution of terminal activity in the presence of quinpirole (green) or 
WIN55 (purple) compared to controls (grey).  (B) No change in fast-releasing terminals. (C to D) 
Quinpriole (green) and WIN55 (purple) induced inhibitory effects in the middle- and slow-






Figure 3.13. D2-R and CB1-R activation on ipsilateral inputs of the DA lesioned hemisphere. 
(A) Differences in the distribution of terminal activity in the presence of quinpirole (green) or 
WIN55 (purple) compared to controls (grey).  (B to D) Quinpriole (green) and WIN55 (purple) 







Similar to previous findings, corticostriatal input activity following chronic DA depletion 
was hypersensitive to D2-R activation (Figure 3.14). This is consistent with reports of an 
upregulation of D2-Rs as well as receptor supersensitivity in the reserpine-treated and DA-
deficient mice (Bamford, Robinson et al. 2004). 
 
Figure 3.14. Quinpirole dose-dependent inhibition of ipsilateral inputs. Ipsilateral inputs in the 
lesioned hemisphere (black squares) were hypersensitive to D2-R activation compared to 
ipsilateral inputs in the intact hemisphere (grey circles) (n = 4 to 8 slices). 
 
Tonic D2-R and CB1-R activation were not detected in ipsilateral cortical inputs within 
the intact (Figure 3.15) and lesioned (Figure 3.16) hemispheres. D2-R antagonist, sulpiride, and 
CB1-R antagonist, AM251 did not change the terminal population distribution when compared 







Figure 3.15. D2-R and CB1-R inhibition on ipsilateral inputs of the DA intact hemisphere. (A to 
D) No differences in distribution of controls (grey) and in the presence of sulpiride (red) or 








 Figure 3.16. D2-R and CB1-R inhibition on ipsilateral inputs of the DA lesioned hemisphere. 
(A to D) No differences in distribution of controls (grey) and in the presence of sulpiride (red) or 








Table 3.4. Median values of D2-R and CB1-R inhibition on ipsilateral activity after DA 
depletion. Inhibition of D2-R by sulpiride and CB1-R by AM251 had no effect on release 
probability in DA intact and DA lesioned hemispheres. (n = 4 to 8 slices). 
 
Aim 2b. How does chronic dopamine depletion affect contralateral corticostriatal activity? 
In chapter 2, we determined that ipsilateral and contralateral corticostriatal inputs behave 
similarly in control conditions and in response to D1 and D2 receptor activation. Following 
unilateral depletion of DA, contralateral inputs experience a depression of overall activity in 







Figure 3.17. Contralateral corticostriatal activity following chronic DA depletion. (A) Schematic 
of contralateral inputs projecting to the DA-intact striatum. (B) Schematic of contralateral inputs 
projecting to the DA-lesioned striatum. (C) Inhibitory effect on average destaining curves of 
contralateral inputs projecting to the lesioned striatum (black squares) compared to contralateral 
inputs projecting to the intact striatum (grey circles) and saline injected controls (white circles) 
(n = 5 to 7 slices). 
 
The distributions of the contralateral inputs from sham and 6-OHDA injected animals are 
represented in normal probability plots (Figure 3.18) and median values of different populations 
of terminals displayed in Table 3.5. Compared to sham, contralateral inputs that project to the 
lesioned striatum exhibited depression of release kinetics primarily in the slow-releasing 
populations of terminals. No change was seen among the three populations in the contralateral 





From Chapter 2, it was determined that ipsilateral and contralateral inputs share similar 
characteristics in WT mice. Here, it appears that the effect of DA depletion on ipsilateral and 
contralateral inputs may also be the same. For this reason, further pharmacological experiments 
on contralateral inputs were not continued in future experiments. 
 
 
Table 3.5. Median values of contralateral activity. Increased latency of contralateral inputs 








Figure 3.18. Chronic DA depletion effects on contralateral probability plots. (A) Contralateral 
inputs in sham controls (white) had similar release profiles to contralateral inputs that project to 
the intact hemisphere of 6-OHDA injected animals (grey). However, slight differences were seen 
in the contralateral inputs that project to the lesioned hemisphere of 6-OHDA injected animals 
(black). (B to C) No inhibition of fast- and middle-releasing terminals in both types of 
contralateral inputs. (D) Contralateral inputs that project to the lesioned hemisphere of 6-OHDA 
injected animals (black) had depressed corticostriatal activity among slow-releasing terminals. (n 






Aim 2a. How does chronic dopamine depletion affect ipsilateral corticostriatal activity? 
 In PD, a neurodegenerative disorder characterized by motor deficits, the loss of DA input 
to the striatum following degeneration of DAergic neurons in the midbrain leads to an imbalance 
of the striatal output pathways. Glutamatergic inputs from the cortex provide the main excitatory 
drive to these striatal output neurons. Therefore, corticostriatal synapses are an important 
influence in the control of motor behavior and are likely target to underlie abnormalities in 
striatal efferents following DA depletion.  
As the dorsolateral striatum is predominantly composed of motor and sensorimotor 
corticostriatal projections (Van Waes, Beverley et al. 2012), focus was placed on adapting FM1-
43 imaging techniques to study the changes in corticostriatal activity in this region following 
chronic DA depletion. Using the unilateral 6-OHDA mouse model of PD, we were able to 
compare the effects of DA depletion on corticostriatal activity in the DA-lesioned and DA-intact 
hemispheres. Injection of 6-OHDA into the left dorsal striatum resulted in motor deficits in the 
right side of the body (contralateral to lesion). The lateralized behavioral response was clearly 
identified in the forelimb motor tests performed in this chapter: the cylinder test and the corridor 






Figure 3.19. Model of chronic DA depletion on corticostriatal activity. (A) During normal motor 
signaling, DA activates D2-Rs on the presynaptic terminal to directly inhibit glutamate release 
and on the postsynaptic terminal to activate retrograde AEA release and activation of CB1-Rs on 
the presynaptic terminal to indirectly inhibit glutamate. (B) Following DA depletion, 
downregulation of CB1-Rs and supersensitive D2-Rs. (C) In the acute slice, the presence of D2-





the addition of CB1-R antagonist, AM251 with quinpirole blocks the D2-CB1-R pathway. D2-R 
inhibition is ameliorated and “filtering” effects are partially restored. 
 
 Our results show that the DA depleted state alters the baseline distribution of ipsilateral 
corticostriatal activity. The overall activity of these ipsilateral inputs were unchanged (average 
t1/2), yet the probability distribution revealed a depression specifically of the slow-releasing 
terminals. With a shift of a greater proportion of terminals to be more active (or faster-releasing) 
this may represent a compensatory change in these terminals to maintain its overall activity level 
compared to the intact hemisphere 
In this chapter, we also provided evidence that activation of D2-Rs significantly reduced 
glutamatergic activity in both the DA-intact and DA-lesioned striatum. In agreement with 
previous studies, we found that ipsilateral corticostriatal inputs to the intact striatum use DA as a 
high-pass filter, in which D2-R activation selectively provided greater inhibition of less active 
(slow-releasing terminals), while exerting little to no inhibitory effect on the most active (fast-
releasing terminals). The loss of this D2-R associated “filtering” effect following chronic DA 
depletion was also in agreement with previous FM 1-43 studies in rodents following acute DA 
depletion by reserpine treatment (Bamford, Robinson et al. 2004). The DA depletion model 
using reserpine treatment induces an acute, nonspecific depletion of biogenic amine stores, in 
contrast with the more selective and slower degeneration of the dopaminergic nigrostriatal 
pathway caused by 6-OHDA. In both acute (reserpine) and chronic (6-OHDA) models, DA 





hypersensitivity to D2-R activation reflected by a larger inhibitory response of corticostriatal 
activity at lower concentrations of the D2-R agonist, quinpirole. This finding was also in 
agreement with those found in the reserpine model (Bamford, Robinson et al. 2004). 
 These studies also provided support for inhibition of glutamate by D2-R activated 
retrograde eCB signaling in the striatum. In the intact hemisphere, quinpirole in the presence of 
CB1-R antagonist, AM251, had a selective inhibitory effect on the less active corticostriatal 
inputs, but to a lesser extent than quinpirole alone. We conclude that quinpirole activated an 
inhibitory response of presynaptic D2-Rs located on the presynaptic corticostriatal terminals, as 
well as an inhibitory response from postsynaptic D2-R mediated retrograde eCB activation. The 
inhibitory effect of quinpirole in the presence of AM251 revealed the inhibitory effect elicited by 
presynaptic D2-Rs. We conclude that presynaptic D2-Rs played a role in the D2-associated 
“filtering” effect by providing inhibition specifically to the slow-releasing terminals. The 
discrepancy between the inhibitory effect with and without AM251 suggests that the D2-R 
activated retrograde eCB signaling also played a role in the D2-associated "filtering" effect. 
Together, the effects of D2-R inhibition appeared to consist of presynaptic and postsynaptic 
components to specifically provide robust inhibition of the least active (slow-releasing) 
terminals. 
 In the lesioned hemisphere, the “filtering" effect of quinpirole that was lost could be 
partially restored in the presence of AM251. When blocking the postsynaptic D2-CB1-R 
retrograde pathway, the most active (fast-releasing) terminals were spared from quinpirole 
inhibition. Thus, in the acute slice, the "filtering" response provided by presynaptic D2-Rs was 





eCBs was lost following chronic DA depletion. When these pre- and post-synaptic effects of D2 
were activated simultaneously (as in the case of quinpirole alone), corticostriatal activity was 
inhibited among all terminals. We conclude that, the filtering effect that was preserved in the 
presynaptic component of D2-R activation was masked by the loss of filtering from the eCBs via 
postsynaptic D2-Rs. Alterations in eCB and CB1-R function can be attributed to the synaptic 
changes resulting from chronic DA lesion – sensitized D2-Rs and overactive eCB signaling. 
After DA depletion the striatum also undergoes structural and functional changes. 
Increases in D2-R sensitivity after DA depletion (Burt, Enna et al. 1975, Schultz 1982) occur 
rapidly and have been linked to changes in mRNA (Calabresi, Benedetti et al. 1988, LaHoste and 
Marshall 1992). Alternative considerations include alteration of the PLC signaling cascade 
(Hernandez-Lopez, Tkatch et al. 2000) or changes in c-fos expression (Paul, Graybiel et al. 1992, 
LaHoste, Yu et al. 1993). Also, a pronounced increase in striatal cells expressing calretinin, a 
calcium binding protein, after DA lesion on side ipsilateral to lesion could be related to changes 
in the DA and glutamate balance (Mura, Feldon et al. 2000). 
Changes in D2-R following chronic DA depletion contribute to the alterations of 
corticostriatal activity seen in the lesioned hemisphere. We will explore how the loss of control 
of glutamate release at the corticostriatal terminals after DA depletion can contribute to the loss 
of motor control by examining if subsequent reinstatement of DA can renormalize both 







Aim 2b. How does chronic dopamine depletion affect ipsilateral corticostriatal activity? 
 Influence of the intact hemisphere on the response to lesion is of importance when using 
unilateral DA denervation models. Previous studies determined reduced sensitivity of DA 
receptors in the striatum contralateral to lesion (Costall, Kelly et al. 1983). Our hypothesis was 
that the contralateral (intact) striatum would be affected by unilateral lesion of DA, however, it 
appeared that the effect of DA depletion on ipsilateral and contralateral inputs may be the same 
in our experiments. In Chapter 2, we also found that ipsilateral and contralateral inputs share 
similar characteristics in WT mice in response to D2-R and CB1-R agonists and antagonists. For 







Dopamine Replacement Therapy  
 
Introduction 
In this chapter, we explore motor behavior and synaptic effects on ipsilateral cortical activity 
after dopamine (DA) replacement therapy by L-DOPA used in combination with treatments to 
promote or suppress endocannabinoid transmission. 
 
L-DOPA  
 L-3,4-dihydroxyphenlalanine (levodopa, or L-DOPA) is the most widely-used and 
effective treatment for Parkinson’s disease (PD).  While there are still no effective treatments to 
delay PD progression, the motor deficits can be attenuated with dopaminergic replacement 
therapy using L-DOPA (Calabresi, Centonze et al. 2000, Picconi, Centonze et al. 2003, Tuite and 
Riss 2003, Olanow, Obeso et al. 2006). DA is synthesized within the DA neurons and terminals 
from the amino acid tyrosine, which is converted to L-DOPA by tyrosine hydroxylase (TH). L-
DOPA is then converted to DA by aromatic amino acid decarboxylase and accumulated by the 
vesicular monoamine transporter (VMAT2) into synaptic vesicles. DA formation from 
exogenous L-DOPA occurs primarily in the striatum, but not exclusively within DA terminals. 
Serotonin neurons also express the enzymes required to convert L-DOPA to DA, and have the 
ability to store DA in synaptic vesicles, protecting it from cytosolic degradation. Following 
extensive death of dopaminergic neurons in PD, serotonergic neurons have been shown to take 





The effects of L-DOPA treatment on motor control and molecular alterations in different 
neuronal systems have been explored in several studies (Calabresi, Centonze et al. 2000, 
Linazasoro 2005, Lundblad, Usiello et al. 2005). The firing of dopaminergic neurons was found 
to be decreased after administration of L-DOPA (Bunney, Aghajanian et al. 1973). CB1-R 
function was not affected in terms of binding, but CB1 mRNA however was increased (Zeng, 
Dass et al. 1999). Additionally, acute L-DOPA treatment has been linked to proteomic changes, 
such as phosphorylation and proteolytic cleavage, of postsynaptic densities, dendrites and axons 
involved in general synaptic transmission and receptor recycling (Scholz, Svensson et al. 2008). 
As these alterations in synaptic structure will ultimately affect synaptic activity, it has been 
proposed that chronic L-DOPA treatment may produce long-lasting changes of neuronal 
synapses and intracellular signaling pathways that ultimately present as dyskinesias (involuntary 
motor fluctuations) (Calabresi, Centonze et al. 2000, Calon, Grondin et al. 2000, Cenci and 
Lundblad 2007). 
Clinically, within minutes of the first dose of L-DOPA, there is a substantial 
improvement of motor disability (Nutt, Woodward et al. 1992, Nutt and Holford 1996); an effect 
that lasts up to a few hours (Contin and Martinelli 2010). High doses of L-DOPA are associated 
with an increased risk of motor complications, such as dyskinesias, in rodents (Lindgren, 
Rylander et al. 2007) and primate models of PD (Maratos, Jackson et al. 2001), as well as PD 
patients (Schrag, Ben-Shlomo et al. 1998). Approximately 30% of PD patients experience 
dyskinesias after 4-6 years of L-DOPA treatment and close to 90% of patients suffer from this 
complication after 9 years (Ahlskog and Muenter 2001). These findings represent the need for 





L-DOPA & Cannabinoids 
 Pharmacological inhibition of corticostriatal hyperactivity may be beneficial in 
treatments for PD. Previously, in chapter 3, we determined that corticostriatal activity is altered 
when the D2-mediated retrograde endocannabinoid (eCB) inhibition pathway is interrupted by 
chronic DA depletion following 6-OHDA lesion. Increased endogenous levels of AEA in 
parkinsonian rodents may reflect a compensatory mechanism to control the cortical 
glutamatergic drive to the striatum. The level of endogenous AEA was three-fold higher in the 
striatum of 6-OHDA lesioned rodents, compared with naive animals, whereas endogenous 2-AG 
was unaffected (Gubellini, Picconi et al. 2002). This effect is attributed to decreased activity of 
both AMT and FAAH (Cravatt, Giang et al. 1996, Maccarrone, Gubellini et al. 2003). Since 
neither the binding of AEA nor the activity of phospholipase D (PLD), a downstream element 
linked to mGluR and DA-R signaling, were affected by 6-OHDA lesion (Gubellini, Picconi et al. 
2002), the general consensus is that a higher level of AEA in the striatum of parkinsonian 
rodents is due to a decreased breakdown of AEA rather than an increased synthesis. We will 
mimic this decrease in AEA cleavage pharmacologically using the FAAH inhibitor, URB597. 
The role of the D2-CB1 co-activation in L-DOPA therapy is suggested by findings that a 
single injection of L-DOPA (50 mg/kg, i.p.) caused a significant elevation of the eCB, 
anandamide (AEA) in the striatum, globus pallidus, and substanstia nigra 1 hour after drug 
administration (with no effect on 2-AG levels).  This elevation of AEA was unique to acute 
administration as chronic L-DOPA produced a modest, statistically insignificant increase in AEA 





pharmacological treatments using L-DOPA in conjunction with CB1-R agonists and antagonists 
as an approach to balance abnormal striatal glutamatergic activity and restore motor behavior.  
 
Cannabinoid Therapies in PD 
The ability of eCB to modulate neurotransmission and synaptic plasticity in basal ganglia 
circuitries has spurred interest in development of cannabinoid-based therapies to treat PD. 
Typically, L-DOPA selectively elevates AEA in different areas of the basal ganglia of normal 
rats via activation of DA D1/D2-Rs. The majority of previous studies report that a single 
injection of L-DOPA (50 mg/kg, i.p.) caused a significant elevation of the eCB, anandamide 
(AEA) in the striatum, globus pallidus, and substanstia nigra 1 hour after drug administration 
(Maccarrone, Gubellini et al. 2003). Additionally, an upregulation of striatal CB1-R mRNA 
levels has also been reported (Zeng, Dass et al. 1999). However, smaller proportion of studies 
report that administration of L-DOPA fails to elevate AEA levels (Ferrer, Asbrock et al. 2003, 
Morgese, Cassano et al. 2007). The general consensus that increased AEA during DA depletion 
is carried through following acute L-DOPA suggests that L-DOPA does not correct eCB 
abnormalities. Studies on the effects of eCB agonist and antagonists on PD motor symptoms 
have produced conflicting results and there is no general consensus on whether cannabinoid-
based therapies may prove beneficial in PD (Meschler and Howlett 2001, van der Stelt and Di 
Marzo 2003, Mesnage, Houeto et al. 2004, Papa 2008). Discrepancies may be attributed to 





the potential of eCB drugs to delay PD progression via eCB receptor-dependent and -
independent mechanisms is promising (Sancho, Calzado et al. 2003, Walter and Stella 2004). 
 
PD Therapies to Decrease Endocannabinoid Transmission 
Since dysfunction of nigrostriatal DAergic neurons can be associated with overactivity of 
the eCB transmission in the BG, CB1-R antagonists may be useful for alleviating the motor 
deficits of PD by attenuating CB1 signaling (Mailleux and Vanderhaeghen 1993, Di, Bisogno et 
al. 2000, Fernandez-Ruiz and Gonzales 2005, Gonzalez, Scorticati et al. 2006). In the first small-
scale, randomized, double-blind, placebo-controlled human study, treatment with rimonabant, a 
selective antagonist of CB1-R with inverse agonist properties, also failed to influence L-DOPA 
induced dykinesia (Mesnage, Houeto et al. 2004). However the dose used in this clinical trial 
was approximately 10-fold lower (0.3 mg/kg versus 3 mg/kg) than a primate study that produced 
positive outcomes (van der Stelt and Di Marzo 2003). Other studies in parkinsonian rodents have 
reported the effectiveness of rimonabant between 0.1 and 1.0 mg/kg in increasing basal 
glutamate release; in control rats, no change in release was detected with doses below 1 mg/kg 
(Fernandez-Espejo, Caraballo et al. 2005, Kelsey, Harris et al. 2009). It should be noted that the 
clinical trial was conducted with a population of patients that all responded well to L-DOPA 
treatment. It is possible that CB1-R blockade is effective only at the very advanced stages of PD, 
consistent with a report of efficacy of rimonabant only occuring in mice with >95% lesion 





mice, observed gender-dependent differences for both the levels of CB1-Rs and motor responses 
to agonist or antagonists (Gonzalez, Scorticati et al. 2006). 
In parkinsonian rodents, systemic injections of the selective CB1 antagonist, rimonabant, 
reduced a variety of behavioral effects indicative of PD in unilateral 6-OHDA rodent 
(Fernandez-Espejo, Caraballo et al. 2005) and increased locomotor activity in rodents with 
bilateral 6-OHDA lesions (Gonzalez, Scorticati et al. 2006). Similarly, rimonabant increased 
motor activity and range of movement, although not bradykinesia or posture, in MPTP-lesioned 
marmosets (van der Stelt and Di Marzo 2003). However, no studies have compared the relative 
efficacy of rimonabant with the standard treatment of L-DOPA for PD, and few have examined 
the interaction between rimonabant and L-DOPA (van der Stelt and Di Marzo 2003).  
Acute systemic doses of rimonabant were more effective at low doses (0.05 to 1 mg/kg) 
than higher doses (Fernandez-Espejo, Caraballo et al. 2005, Kelsey, Harris et al. 2009). 
Interestingly, the CB1-R antagonist, rimonabant can be therapeutic by itself as a monotherapy 
and can also enhance the therapeutic effect of a moderate, but not high dose of L-DOPA (Kelsey, 
Harris et al. 2009).  Specifically, the combination of low dose L-DOPA (8mg/kg) with low dose 
rimonabant (0.05 mg/kg) partially counterbalanced behavior lateralization (Kelsey, Harris et al. 
2009). Therefore, incorporation of eCB antagonists may enable a reduction in the dose (and 








PD Therapies to Increase Endocannabinoid Transmission 
Cannabinoid agonists are unlikely to be used for treating bradykinesia in PD because of 
their hypokinetic response profile both in primates and humans (Consroe 1998, Muller-Vahl, 
Kolbe et al. 1999, Romero, Lastres-Becker et al. 2002, Brotchie 2003, Croxford 2003). This 
evidence would suggest that increasing eCB transmission should contribute to PD symptoms. 
Increased AEA tone can be achieved by AMT or FAAH blockade, which may restore normal 
corticostriatal function. This effect was reported by pharmacological inhibition of FAAH which 
produced a depression of striatal glutamatergic activity (Gubellini, Picconi et al. 2002). 
However, in reserpine-treated and bilateral 6-OHDA lesioned mice, the combination i.p. 
treatment of D2 agonist, quinpirole (1.5 mg/kg), and FAAH inhibitor, URB 597 (1 mg/kg) 
significantly decreased catalepsy (muscle rigidity/fixed posture) and increased locomotion; either 
treatment alone had no effect (Kreitzer and Malenka 2007).  
Clinical trials that directly increased eCB presence by administering cannabis extract 
failed to show motor effects, and surveys on cannabis use to improve PD motor symptoms 
provided confusing data (Carroll, Bain et al. 2004, Benarroch 2007). However, results from one 
survey have shown improvements of both parkinsonian symptoms and dyskinesias after a latency 
of months of cannabis use with no clear explanation (Venderova, Ruzicka et al. 2004).  
Taken together, although previous studies do not offer a complete understanding of the 
role of eCBs and CB-Rs in PD, they support the notion that D2-Rs and the eCB system play an 
important role in movement disorders including PD, and may provide a framework for novel 





and motor behavior after L-DOPA i.p. injections used in combinatorial treatments to promote 
and suppress endocannabinoid transmission is addressed in the following aim: 
 
Aim 3. How do treatments to replace dopamine and endocannabinoid function affect 
corticostriatal activity and motor behavior? 
 
Methods 
Dopamine and Endocannabinoid Therapies 
In some cases, animals were injected with the CB1-R antagonist, AM251 (1 mg/kg) (Tocris 
Bioscience) or fatty acid amide hydrolase (FAAH) inhibitor URB597 (3 mg/kg), which catalyzes 
the breakdown of AEA (Figure 4.1). Both drugs were dissolved in 5% Tween-80 in 0.9% saline 
and sonicated immediately prior to intraperitoneal (i.p.) injection. Animal not receiving AM251 
or URB597 received i.p. injection of the same amount of vehicle. According to their 
pharmacokinetic properties (Kathuria, Gaetani et al. 2003, Patel and Hillard 2006), AM251 or 
URB597 were administered 15 minutes prior to treatment with L-DOPA (L-3,4-
dihydrophenylalanine methyl ester or methyl levodopa). L-DOPA (5 mg/kg) was combined with 
benserazide (12 mg/kg) (Sigma-Aldrich), to reduce the metabolism of L-DOPA in peripheral 
tissues and maximize the amount that entered the CNS. Both were dissolved in saline solution 





received i.p. injection of the same amount of benserazide in saline solution. All injections were 
administered in a volume of 5 mL/kg. 
 
 
Figure 4.1. Experimental time course of injections. (A) To modify eCB transmission, AM251 or 
URB597 were administered. Animals not tested with eCB modulators were injected with vehicle 
(Tween-80). (B) Fifteen minutes following treatment #1, some animals received DA replacement 
therapy with L-DOPA. All others were injected with vehicle (benserazide in 0.9% saline 
solution). (C) Thirty minutes following treatment #2, behaviour tests were performed. 
 
Behaviour Tests 
See Chapter 3 for methods. Additionally, to habituate each mouse to i.p. injections, during the 
three days prior to testing, mice were administered vehicle (0.9% saline) injections i.p. 30 
minutes prior to habituation to the corridor apparatus. Endogenous DA rapidly increases after 
administration, reaching a maximal concentration 45 minutes after L-DOPA administration and 





tests were performed 30 minutes following L-DOPA treatment as was described in previous 
experiments (Calabresi, Centonze et al. 2000, Picconi, Centonze et al. 2003). 
 
Results 
Aim 3. How do treatments to replace dopamine and endocannabinoid function affect 
corticostriatal activity and motor behavior? 
 
Forelimb akinesia behavior tests were performed 30 minutes following L-DOPA i.p. 
treatment to assess renormalization of limb use (Figure 4.2). Cylinder tests showed that sham 
injected mice had a 51.6% left limb use. Following vehicle (12 mg/kg benserazide) or L-DOPA 
(5 mg/kg with 12 mg/kg benserazide) i.p. injection, limb use was unchanged: 50.5% and 50.1%, 
respectively. In 6-OHDA injected mice, cylinder tests showed 68.1% left limb use which was 
unchanged following vehicle i.p. injection (66.7%); however, left limb use was renormalized 
following L-DOPA i.p. treatment (45.0%). Similarly, the corridor tests showed that saline 
injected mice displayed 52.4% left retrievals. Following vehicle (12 mg/kg benserazide) or L-
DOPA (5 mg/kg with 12 mg/kg benserazide) i.p. injection, retrievals was unchanged: 51.9% and 
51.1%, respectively. In 6-OHDA injected mice, cylinder tests showed 94.5% left retrievals 
which was unchanged following vehicle i.p. injection (87.9%). However, following L-DOPA i.p. 
treatment, retrieval preference was reversed (33.0% left; 67.0% right) so that there was an 






Figure 4.2. Renormalization of forelimb behaviour following L-DOPA i.p. injection. (A) 
Schematic of cylinder (top) and corridor (bottom) tests used to assess lateralized motor 
behaviour (Grealish 2010). (B) Sham mice had no limb preference in cylinder tests (left) and 
corridor tests (right). No change following vehicle (white) and L-DOPA (red) i.p. injections. (C) 
In the cylinder test, 6-OHDA injected mice (black) left limb preference was unchanged with 
vehicle (white) but was reversed with L-DOPA (red) i.p. injection. (D) In the corridor test, 6-
OHDA injected mice (black) left retrieval preference was unchanged with vehicle (white) but 








Figure 4.3. Behavior asymmetry following L-DOPA i.p. injection. (A) In the cylinder test, 
compared to saline controls, there was a decrease in the right limb use following 6-OHDA. With 
L-DOPA i.p. treatment, usage of both limbs was decreased (n = 4 to 90 mice; compared to saline: 
* p < 0.05; compared to 6-OHDA * p < 0.05; ANOVA Dunnett’s post-test) (B) In the corridor 
test, compared to saline controls, there was a decrease in the right and an increase in left 
retrievals following 6-OHDA. With L-DOPA i.p. treatment, use of the left limb was decreased 
but use of the right limb was increased. (n = 4 to 90 mice; compared to saline * p < 0.0001; and 
compared to 6-OHDA * p < 0.0001; ANOVA Dunnett’s post-test). 
 
In addition to changes in forelimb preference L-DOPA i.p. injection also reduced the 
amount of limb use (Figure 4.3). In the cylinder test, the average number of left limb uses in 6-
OHDA injected mice was unchanged from saline controls (nl = 31.3 in 6-OHDA versus nl = 33.5 
in saline) but a significant decrease in right limb uses was apparent (nr = 21.9 in 6-OHDA versus 





unchanged compared to mice before treatment (nr = 19.9 after L-DOPA versus nr = 21.9 before); 
however, the number of left limb uses dramatically decreased (nl = 17.0 after L-DOPA treatment 
versus nl = 34.4 before treatment). In the corridor test, the number of left retrievals in 6-OHDA 
injected mice was significantly increased from saline controls (nl = 9.7 in 6-OHDA versus nl = 
5.9 in saline) while the right retrievals was significantly decreased (nr = 2.0 in 6-OHDA mice 
versus nr = 5.7 in saline mice). Following L-DOPA i.p. treatment, the number of right retrievals 
was increased compared to mice without treatment (nr = 4.9 after L-DOPA versus nr = 2.0 before 
treatment), whereas the number of left retrievals was drastically decreased (nl = 3.0 after L-
DOPA versus nl = 9.7 before treatment). It is possible that this finding of reduction in activity 
was confounded by the mild rotational behavior induced by acute L-DOPA (Brannan, Prikhojan 
et al. 1998). Therefore, AM251 pre-treatment may have ameliorated the rotational behavior (El-
Banoua, Caraballo et al. 2004) and not necessarily increased the number of limb uses. 
Comparing corticostriatal activity before and after L-DOPA treatment (Figure 4.4), there 
was a long-lasting depression in baseline activity in control conditions after treatment (t1/2 = 283 
before versus t1/2 = 349 after L-DOPA). Additionally, the dose-dependent inhibitory effects of 
quinpirole were no longer present (Figure 4.4C). The effect of L-DOPA induced a long-lasting 
change in the corticostriatal terminals that saturated the D2R-mediated inhibition such that, in the 
acute slice, activation of D2-Rs by quinpirole had no effect on overall activity. 
The distributions of the ipsilateral inputs before (Figure 4.5) and after (Figure 4.6) L-
DOPA treatment are represented in normal probability plots and median values of different 
populations of terminals are displayed in Table 4.1. Comparing before and after L-DOPA 





populations. After L-DOPA treatment, quinpirole in acute slices produced an inhibitory effect on 
slow-releasing terminals. DA replacement therapy was able to modify the corticostriatal inputs 
so that the D2-R mediated "filtering" that was lost after DA depletion was able to function again. 




Figure 4.4. D2-R activation of ipsilateral inputs following acute L-DOPA treatment. (A) 
Ipsilateral inputs following chronic DA depletion before L-DOPA treatment were hypersensitive 
to quinpirole (green). (B) Ipsilateral inputs in the lesioned striatum had significantly depressed 
average t1/2 values in control conditions (grey) following acute L-DOPA treatment. This 
depressed activity was unchanged in the presence of quinpirole (green) and quinpirole + AM251 
(blue).  (C) Ipsilateral inputs in the lesioned hemisphere (black) were hypersensitive to D2-R 
activation compared to ipsilateral inputs in the intact hemisphere (white). Following L-DOPA 
treatment (red), quinpirole’s dose-related inhibitory effect reached a plateau at all concentrations 






Figure 4.5. D2-R effects on ipsilateral inputs before L-DOPA treatment. (A) Differences in the 
distribution of terminal activity between ipsilateral inputs in controls (grey), in the presence of 
quinpirole (green), and quinpirole + AM251 (blue).  (B to D) Significant inhibition of all three 
populations with quinpirole (green) was ameliorated by addition of AM251 with quinpirole 
(blue), especially in the fast- and slow-releasing populations of terminals (n = 6 to 8 slices; ** p 






Figure 4.6. D2-R effects on ipsilateral inputs after L-DOPA treatment. (A) Differences in the 
distribution of terminal activity distribution between ipsilateral inputs in controls (grey), in the 
presence of quinpirole (green).  (B to C) No change in fast- and middle-releasing terminals. (D) 
Significant inhibition of slow-releasing populations with quinpirole (green) was ameliorated by 








Table 4.1. Median values of D2-R effects on ipsilateral activity after L-DOPA. In control 
conditions, inhibitory effect of L-DOPA treatment in fast- and middle-releasing terminals. 
Inhibitory effect of D2 activation by quinpirole in slow-releasing population after L-DOPA 
treatment, was blocked after addition of CB1-R antagonist AM251 (Quin + AM) (n = 4 to 8 
slices). 
 
We next examined the effectiveness of L-DOPA i.p. injections in combination treatments 
to promote or suppress eCB transmission. To decrease eCB transmission, we pre-treated DA-
depleted mice with the CB1-R antagonist AM251 (1 mg/kg). To increase eCB transmission, we 
pre-treated DA-depleted mice with the FAAH inhibitor URB597 (3 mg/kg). Both eCB 
treatments were administered 15 minutes prior to L-DOPA treatment. Forelimb akinesia behavior 
tests were performed 30 minutes following L-DOPA i.p. injection to assess renormalization of 
limb use (Figure 4.7). Cylinder tests showed that AM251 pre-treatment (50.5% left; 49.5% right) 
renormalized motor function without inducing a right limb preference, as was demonstrated with 
L-DOPA alone (45.0% left; 55% right). Pre-treatment with URB597 (32.0% left; 68% right) 
exacerbated the slight overcompensation of the right forelimb seen with L-DOPA alone. 





43.5% right), whereas a right retrieval preference was induced with URB597 treatment (33.8% 
left; 66.2% right) that was similar to L-DOPA alone (33.0% left 67.0% right). 
 
 
Figure 4.7. Combination treatments of eCB modulators with L-DOPA i.p. injection. (A) In the 
cylinder test, 6-OHDA injected mice (black) limb preference was reversed with L-DOPA (red). 
Overcompensation of the right limb was ameliorated with AM251 + L-DOPA (green) but 
worsened with URB597 + L-DOPA (blue) treatment.  (B) In the corridor test, 6-OHDA injected 
mice (black) left limb preference was reversed with L-DOPA (red). Overcompensation of the 
right limb was ameliorated with AM251 + L-DOPA (green) but worsened with URB597 + L-








Figure 4.8. Behavior asymmetry renormalized with AM251 + L-DOPA i.p. injection. (A) In the 
cylinder test, following AM251 + L-DOPA (green) treatment, the number of left and right limb 
uses was restored to saline control levels. With URB597 + L-DOPA (blue) treatment, both left 
and right limb uses were less than saline controls and right limb preference was similar to L-
DOPA treatment alone (red) (n = 4 to 90 mice; compared to saline: * p < 0.05, *** p < 0.0001; 
compared to 6-OHDA * p < 0.05, *** p < 0.0001, ANOVA Dunnett’s post-test). (B) In the 
corridor test, number of retrievals was restored to saline levels with AM251 + L-DOPA. With 
URB597 + L-DOPA (blue) treatment, the number of left retrievals was restored however, the 
number of right retrievals was significantly increased (n = 4 to 90 mice; compared to saline: * p 
< 0.0001; compared to 6-OHDA * p < 0.0001, ANOVA Dunnett’s post-test) 
 
In addition to renormalization of forelimb preference, AM251 + L-DOPA i.p. injection 
also renormalized amount of limb use (Figure 4.8). In the cylinder test, following AM251 + L-





with AM251 + L-DOPA versus nr = 33.5 in saline) and the number of left limb uses was 
maintained (nl = 33.0 with AM251 + L-DOPA versus nl = 31.1 in saline). With URB597 + L-
DOPA treatment, both left and right limb uses were less than saline controls and there was a 
right limb preference (nl = 21.6 and nr = 27.4) similar to what was seen with L-DOPA treatment 
alone. In the corridor test, following AM251 + L-DOPA treatment, the number of limb uses (nl = 
5.7 and nr = 4.4) was restored to saline control levels. With URB597 + L-DOPA treatment, the 
number of left limb uses was restored to saline control levels (nl = 5.4 with URB597 + L-DOPA 
versus nl = 5.9 in saline); however, the number of right limb uses was significantly increased (nr 
= 8.6 with URB597 + L-DOPA versus nr = 5.7 in saline). The right limb preference seen with L-
DOPA treatment alone was exacerbated with the addition of URB597. 
In comparisons between corticostriatal activity after AM251 + L-DOPA and URB597 + 
L-DOPA treatment (Figure 4.9), there was a depression in overall baseline activity after URB597 
treatment (t1/2 = 362) similar to that of L-DOPA treatment alone (t1/2 = 349), which was not 
present following AM treatment (t1/2 = 325). Additionally, inhibitory effects of in the acute slice 
quinpirole were no longer present with URB597 treatment (t1/2 = 371), yet were preserved with 
AM251 treatment (t1/2 = 372). The combination of quinpirole and AM251 in the acute slice 
ameliorated D2-R inhibition following both URB (t1/2 = 346) and AM251 treatment (t1/2 = 357).  
The effect of URB597 + L-DOPA  was similar to L-DOPA alone in that the treatment induced a 
long-lasting change in the corticostriatal terminals that saturated the D2R-mediated inhibition 
such that in the acute slice activation of D2-Rs by quinpirole had no effect on activity. This 






Figure 4.9. D2-R activation of ipsilateral inputs following pre-treatment with AM251 and 
URB597 prior to L-DOPA. (A) Ipsilateral inputs following AM251 + L-DOPA treatment were 
inhibited by quinpirole (green). D2-R inhibition was ameliorated by the addition of AM251 
(blue) (B) Ipsilateral inputs following URB597 + L-DOPA  treatment were not inhibited by 
quinpirole (green) or quinpirole + AM251 (blue) (n = 4 to 6 slices, * p < 0.05, Mann-Whitney 
test). 
 
The distributions of the ipsilateral terminal activities after AM251 + L-DOPA (Figure 
4.10) and URB597 + L-DOPA (Figure 4.11) treatment are represented in normal probability 
plots and median values of different populations of terminals displayed in Table 4.2. With AM + 
L-DOPA and URB + L-DOPA treatments, the addition of quinpirole in the acute slice had an 
inhibitory effect on the least active (slow-releasing) terminals, which was abolished with the 







Figure 4.10. D2-R effects on ipsilateral inputs after AM251 + L-DOPA treatment. (A) 
Differences in the distribution of terminal activity between ipsilateral inputs in controls (grey), in 
the presence of quinpirole (green).  (B) No difference in fast-releasing terminals. (C to D) 
Significant inhibition of middle- and slow-releasing populations with quinpirole (green) was 







Figure 4.11. D2-R effects on ipsilateral inputs after URB597 + L-DOPA treatment. (A) 
Differences in the distribution of terminal activity between ipsilateral inputs in controls (grey), in 
the presence of quinpirole (green).  (B to C) No change in fast- and middle-releasing terminals. 
(D) Significant inhibition of slow-releasing population with quinpirole (green) was ameliorated 








Table 4.2. Median values of D2-R effects on ipsilateral activity following pre-treatment with 
AM251 and URB597 prior to L-DOPA. In control conditions, inhibitory effect ofURB597 + L-
DOPA treatment in fast- and middle-releasing terminals. After AM251 pre-treatment, inhibitory 
effect of D2 activation by quinpirole on middle- and slow-releasing populations was blocked by 
addition of the CB1-R antagonist, AM251 (Quin + AM). After URB597 ptre-treatment, 
inhibitory effect of quinpirole on slow-releasing populations was blocked by addition of AM251 
(n = 4 to 8 slices). 
 
Discussion 
Aim 3. How do treatments to replace dopamine and endocannabinoid function affect 
corticostriatal activity and motor behavior? 
 In Chapter 3, we demonstrated that corticostriatal inputs use DA as a high-pass “filter”, in 
which D2-R activation selectively provides greater inhibition of less active (slow-releasing 
terminals), while exerting little to no inhibitory effect on the most active (fast-releasing 
terminals). This “filtering” was absent in the DA-depleted state but partially restored in the 
presence of quinpirole and AM251 in the acute slice, suggesting that the loss in “filtering” was a 





activation pathway in the behaving animal may restore DA’s role in selective inhibition of 
corticostriatal inputs and subsequently restore motor behavior. 
 Behavior testing revealed an alteration of forelimb motor function following L-DOPA 
injection in which ~70% of mice displayed an over-normalization of motor function: an overuse 
of the right (affected) limb compared to the left (unaffected) limb. Additionally, L-DOPA 
treatment decreased overall limb use especially in the unaffected left limb. These L-DOPA 
induced decreases in limb use were unexpected and were likely a result of L-DOPA-induced 
rotational behavior (Brannan, Prikhojan et al. 1998) despite the low doseage of L-DOPA (5 
mg/kg) administered used in these experiments compared to established therapies. Further 
experimentation with multiple dose regimens could resolve this issue. 
At the level of the striatal microcircuit, L-DOPA can be converted to DA via serotonin 
neurons within the DA depleted hemisphere (Ng, Chase et al. 1972, Melamed, Hefti et al. 1980) 
(Figure 4.12). This sudden, unregulated release of DA in a previously DA depleted state has been 
found to induce a variety of structural changes and adaptive rearrangement of synapses: ΔFosB 
mRNA, a potential modulator of gene expression, is increased (Doucet, Descarries et al. 1986, 
Andersson, Konradi et al. 2001, Valastro, Andersson et al. 2007) amd subsequently increases 
Cdk5, a downstream target that controls efficacy of dopaminergic PKA signaling via positive 
feedback mechanism (Lew, Huang et al. 1994), significant increase in ERK1/2 phosphorylation 
in striatal neurons and its downstream targets involved in the regulation of protein translation and 
gene transcription (Westin, Vercammen et al. 2007, Santini, Alcacer et al. 2009), structural 
changes include proteomic alterations of proteins involved in general synaptic transmission and 





projection neuron expressing the calcium binding protein, calretinin (Mura, Feldon et al. 2000). 
These structural and functional synaptic changes following acute L-DOPA treatment, could 
account for the inhibition of baseline corticostriatal activity compared to that before treatment. 
Also, following L-DOPA treatment, the presence of quinpirole in the acute slice induced 
a selective D2-R inhibition of the least active corticostriatal terminals indicating a role of L-
DOPA to restore D2-R “filtering” (Figure 4.13C). Pre-treatment with the FAAH inhibitor, 
URB597, prior to L-DOPA resulted in similar changes in behavior and corticostriatal activity 
compared to L-DOPA alone. The treatment regime with URB597 allowed a prolonged presence 
of AEA in the synapse to enhance eCB-mediated inhibition on corticostriatal terminals. 
Although overall behavior activity was increased compared to L-DOPA alone, the overuse of the 
right limb was exacerbated with URB597 pre-treatment. 
The treatment regime that provided motor behavior recovery closest to saline controls 
was pre-treatment with CB1-R antagonist, AM251, prior to L-DOPA injection. The effect of the 
combination of low dose CB1-R antagonist, rimonabant, with low dose L-DOPA has also been 
reported in previous studies using different behavior test and DA depleted rodents (Fernandez-
Espejo, Caraballo et al. 2005, Kelsey, Harris et al. 2009). In our experiments, circling behavior 
was minimal, allowing for proper execution of behavioral tasks so that the number of limb uses 
of the unaffected (left; ipsilateral to lesion) and affected (right; contralateral to lesion) sides was 
similar to that of sham mice. Additionally, baseline corticostriatal activity was not as severely 
depressed compared to treatments with L-DOPA alone or URB + L-DOPA. Therefore, we 
suggest that L-DOPA treatment creates a long-lasting change in corticostriatal activity that can be 






Figure 4.12. Model of L-DOPA effects during chronic DA depletion. (A) During normal motor 
signaling, DA activates D2-Rs on the presynaptic terminal to directly inhibit glutamate release. 
Activation of D2-Rs on the postsynaptic terminal activates retrograde anandamide release and 
activation of CB1-Rs on the presynaptic terminal to indirectly inhibit glutamate. (B) Following 
DA depletion, downregulation of CB1-Rs and supersensitive D2-Rs. (C) In the presence of L-
DOPA, unregulated release of DA from serotonin (5-HT) inputs activates D2-Rs resulting in a 





 To model the corticostriatal activity in the behaving animal, we compare corticostriatal 
activity measured by FM 1-43 in acute slices (Figure 4.13). In acute slices of DA intact, and DA 
lesioned animals with no treatment, L-DOPA i.p., or URB597 + L-DOPA i.p., corticostriatal 
activity in the presence of D2-R activation with quinpirole may best represent the activity in the 
behaving animal (Figure 4.14). In acute slice of DA lesioned animals with AM251 + L-DOPA 
i.p. treatment, corticostriatal activity in the presence of quinpirole and CB1-R antagonist, 
AM251, may best represent the activity in the behaving animal (Figure 4.14). Comparing these 
conditions (Figure 4.13) to the DA intact hemisphere (t1/2 = 347.9 sec), corticostriatal activity 
was depressed: (1) in the DA depleted state (t1/2 = 386.5 sec), (2) following L-DOPA treatment 
(t1/2 = 360.0 sec), and (3) following URB-597 + L-DOPA (t1/2 = 371.4 sec). However, 
corticostriatal activity was enhanced following (4) AM + L-DOPA treatment (t1/2 = 337.4 sec). 
 
Figure 4.13. Comparison of corticostriatal activity. Overall corticostriatal activity was depressed 
during DA lesion and followed by L-DOPA treatment or URB597 + L-DOPA treatment, whereas 






Figure 4.14. Model of corticostriatal activity in the behaving animal. (A) In the normal, DA 
intact, state, DA acting on D2-Rs can be modeled in the acute slice with the superfusion of 
quinpirole. DA acts on presynaptic and postsynaptic D2-Rs to induce an inhibitory effect on 
presynaptic corticostriatal activity. (B) Following DA depletion, any remaining DA will activate 
D2-Rs to induce a highly inhibitory state due to the combination of downregulation of CB1-Rs 





serotonin (5-HT) inputs activates D2-Rs resulting in an inhibition of glutamate release. (C) 
Following AM251 + L-DOPA treatment, unregulated release of DA from serotonin (5-HT) 
inputs activates D2-Rs but the D2-CB1-R coactivation pathway is inhibited so that inhibition is 
lessened compared to treatment with L-DOPA alone. 
 
Comparing the distributions of terminal activities, treatment with L-DOPA alone and 
URB597 + L-DOPA are similar, and DA selective inhibition is restored (Figure 4.15). However, 
the distribution of corticostriatal activity that most resembles normal DA intact activity is during 
treatment with AM251 + L-DOPA (Figure 4.16). 
 In summary, the combination of low dose AM251 + low dose L-DOPA restores proper 
motor behavior as well as proper DA selective inhibition of corticostriatal activity in 6-OHDA 
unilateral DA depletion mice. These findings of combination treatment of CB1-R antagonist with 
L-DOPA provide further evidence in agreement with previous studies in other PD rodent models 
using other forelimb behavior tests (Gonzalez, Scorticati et al. 2006, Kelsey, Harris et al. 2009). 
These data support the view that the adjunctive use of a cannabinoid antagonist might enable a 










Figure 4.15. Comparison of corticostriatal activity distributions during L-DOPA and URB597 + 
L-DOPA treatment. The D2-R selective inhibition that was lost during DA lesioning (dark grey) 
was restored to near normal (DA Intact; light grey) levels during L-DOPA (red) and URB597 + 






Figure 4.16. Comparison of corticostriatal activity distributions during L-DOPA and AM251 + 
L-DOPA treatment. The D2-R selective inhibition that was lost during DA lesioning (dark grey) 
was restored to near normal (DA Intact; light grey) levels during L-DOPA (red), and fully 







Summary and Conclusions 
 
 These experiments demonstrate that DA modulation of the cortical inputs to the striatum 
have important functional implications in motor signaling following long-term DA depletion and 
subsequent DA replacement therapies. Specifically, we found a correlation between normal 
motor function and the presence of the D2-R "filtering" of corticostriatal inputs which consisted 
of a direct response by presynaptic D2 receptors and an indirect response by postsynaptic D2 
receptors via retrograde endocannabinoid inhibition. We also identified a prominent role of eCBs 
in corticostriatal function that can interfere with both normal D2-R "filtering" and behavior, 
interactions with DA in the striatum, and pathological changes following DA depletion and DA 
replacement therapy with L-DOPA. Our data support the view that combinatorial use of L-
DOPA with a cannabinoid antagonist might provide improved treatments for PD. We note 
however that eCBs are expected to have multiple effects, as CB1-Rs are located throughout the 
CNS. Appropriate use of such drugs may require significant attention to dosage, timing, and 
coordination with dopaminergic therapies. 
 
Presynaptic versus Postsynaptic D2-Rs 
 Our experiments confirmed differential roles of presynaptic and postsynaptic D2-R 
activation following chronic DA depletion. Specifically, it was the D2-CB1-R co-activation 
pathway that ultimately produced a loss of “filtering” associated with loss of motor function. 





postsynaptic D2-Rs. However, studies have determined that D2-Rs exist in two isoforms: D2s 
(short) variant is highly expressed on presynaptic neurons whereas the D2L (long) variant is 
found postsynaptically on neurons throughout the striatum (Lindgren, Usiello et al. 2003, 
Centonze, Gubellini et al. 2004). Future experiments to explore the function of these two variants 
could potentially provide valuable insights into how D2-R “filtering” occurs. To extend our 
findings that presynaptic D2-R “filtering” was preserved in the DA depleted state, we would be 
most interested in determining if rodents with genetic modifications of the two D2-R isoforms: 
Drd2loxP/loxP; Dat+/IRES-cre (Bello, Mateo et al. 2011), D2Rfloxflox/En1Cre/+ (Anzalone, Lizardi-Ortiz et 
al. 2012), D2Rfloxflox/D1Cre/+ (Anzalone, Lizardi-Ortiz et al. 2012), and D2L-/- (Lindgren, Usiello et 
al. 2003, Centonze, Gubellini et al. 2004) could retain motor function and normal D2 “filtering” 
following chronic DA depletion.  
 
D2-CB1-R Co-activation 
 Manipulation of the D2-CB1-R pathway to ultimately provide treatment of human 
disease will require a thorough understanding of the roles of different eCBs, their sources, and 
the stimuli that mobilize them. To date, there are numerous gaps of knowledge that are yet to be 
uncovered. eCBs are a family of lipid messengers that are made on demand through cleavage of 
membrane precursors (Piomelli 2003). As lipids, eCBS cannot be stored in vesicles, but their 
quantities increase with stimulation, leading to the concept that eCBs are synthesized and 
mobilized as needed (Julian, Martin et al. 2003, Piomelli 2003). In contrast to conventional 





diffusion across the plasma membrane (Felder and Glass 1998). It is unknown if eCBs can 
remain within a cell without being released and whether all stimuli generate the same eCBs.  
 In general, it is suggested that eCBs are directly synthesized from membrane 
phospholipids in response to an increase in postsynaptic intracellular Ca2+ alone, or combined 
with activation of GPCRs, such as mGluRs (Jung, Mangieri et al. 2005). Two hypotheses for 
AEA biosynthesis are often debated: the first suggests activation of both phospholipase A2 and 
phospholipase D (PLD) to release precursors that then bond to form AEA (Hernandez-Lopez, 
Tkatch et al. 2000, Senogles 2000); an alternative pathway suggests a Ca2+-dependent N-
acyltransferase (NAT) formation of precursors that are converted to AEA by PLD (Piomelli 
2003, Liu, Wang et al. 2008, Okamoto, Tsuboi et al. 2009). The biosynthesis of 2-AG is better 
understood: Ca2+ stimulated phospholipase C (PLC) transforms membrane phosphoinositides 
into diacylglcerol (DAG) which is hydrolyzed to 2-AG by DAG lipase (DGL) (Piomelli, Astarita 
et al. 2007). Technical limitations complicate determinations of which eCBs (AEA or 2-AG) are 
active at a given synapse. Since eCBs are released in minute quantities and are rapidly taken up 
and degraded, biochemical techniques can detect amounts of 2-AG and AEA in tissues, but lack 
temporal and spatial resolution (Piomelli, Astarita et al. 2007). 
 In our experiments, we suggest that activation of D2-Rs on the postsynaptic membrane 
can directly induce synthesis and release of eCBs. The hallmark of D2-R signaling is an 
inhibition of cAMP formation and intracellular Ca2+ accumulation, which would negatively 
regulate NAT activity and prevent AEA formation. Alternatively, D2-Rs could interact with the 
Rho family of G proteins to stimulate PLD activity (Senogles 2000) or may utilize the βγ 





signaling cascade could catalyze the cleavage of membrane phosphoinositides which might then 
recruit the NAT/PLD pathway by mobilizing Ca2+. In this way, D2-R activation could directly 
induce formation and release of eCBs. This hypothesis is similar to that suggested of mGluR-
mediated activation of eCBs in which mGluR1s are linked through Gq/11 to the activation of 
PLCβ to produce 2-AG (Piomelli 2003, Jung, Mangieri et al. 2005). To extend our findings that 
activation of D2-Rs on the postsynaptic membrane can directly induce synthesis and release of 
eCBs, we would be most interested in determining if inhibitors of PLC and PLD could prevent 




 Further exploration of the cannabinoid circuitry could be valuable to understanding the 
effect of the cannabinoid system on corticostriatal activity. The endogenous cannabinoid, AEA, 
can be activated by receptors other than CB1-R (Zygmunt, Petersson et al. 1999, De Petrocellis, 
Bisogno et al. 2001). The transient receptor potential vanilloid 1 (TRPV1) are ionotropic 
cannabinoid receptors that are highly expressed in dopaminergic regions, including the cortex, 
hippocampus, striatum, and midbrain (Toth, Boczan et al. 2005). Although the affinity of AEA 
in the low micromolar range is lower for TRPV1-Rs than its affinity for CB1-Rs (Di, Bisogno et 
al. 2000, van der Stelt and Di Marzo 2003), once activated, TRPV1-Rs can also increase DA 
firing rate through excitatory TRPV1-Rs located on glutamatergic terminals (Marinelli, Di 
Marzo et al. 2007). An interesting future direction will be to determine if the cannabinoid effects 
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